STOCK TITAN

Cyabra's nine-month net loss widens to $16.8M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Cyabra, Inc. (CYAB) reported nine-month revenue of $5.271 million, up 29% from $4.078 million, while net loss increased to $16.801 million from $8.501 million. Annualized recurring revenue (ARR) was $8.3 million as of September 30, 2026, versus $6.7 million a year earlier. Operating cash use was $9.567 million, and cash and equivalents were $1.342 million at quarter-end. Management said substantial doubt exists about the company’s ability to continue as a going concern.

On November 9, 2026, Cyabra received an initial $650,000 tranche under a secured note with principal financing of up to $1.5 million; outstanding amounts accrue 10% annual interest and are due January 15, 2027, subject to the lender’s extension rights. On November 15, it agreed to a private placement for up to approximately $45.6 million. The contemplated initial closing is approximately $15.6 million and is subject to stockholder approvals and Nasdaq confirmation that listing deficiencies were cured and continued listing approved; it had not occurred as of issuance.

Stockholders authorized the board to effect a 1-for-30 reverse split on November 10, 2026, expected to become effective later in November. On November 12, the company granted 17,700,000 RSUs to executives, directors, advisors and employees.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 2 points

How the balance works

Positive

  • Moderate pointNine-month revenue increased 29% to $5.271 million.

Negative

  • Major pointNine-month net loss increased to $16.801 million from $8.501 million.
  • Major pointSubstantial doubt exists about Cyabra’s ability to continue as a going concern.

Filing Explained

At September 30, the filing listed 79,847 thousand potentially issuable shares, alongside 9,756,323 common shares already issued in the conversions.

The unaudited quarterly report records that the September 9, 2026 conversion of all Series A and B preferred shares and exchange of all Series C preferred shares were completed; none remained outstanding at September 30, 2026. The transactions issued 9,756,323 common shares and left warrants for additional shares; the issued stock reduces existing common holders’ percentage ownership absent offsetting changes, and exercise of the warrants could add further dilution.

The Series A/B conversion produced pre-funded warrants for up to 25,006,895 shares, while Series C was exchanged for pre-funded warrants for up to 24,505,747 shares plus Series A and Series B warrants for 24,505,747 shares each. Those warrant shares are potential, not already issued: pre-funded warrants carry a $0.0001 exercise price, and Series A and B warrants carry exercise prices of $0.50 and $0.45 per share, respectively.

Separately, the filing reports 79,847 thousand potentially issuable shares as of September 30, excluded from diluted loss per share as anti-dilutive; this is a potential-share measure, not a report that those shares had all been issued.

Revenue $5.271 million Nine months ended September 30, 2026; $4.078 million in the same 2025 period, a 29% increase.
Annualized recurring revenue (ARR) Approximately $8.3 million As of September 30, 2026, compared with approximately $6.7 million as of September 30, 2025; 24% increase.
Net loss $16.801 million Nine months ended September 30, 2026; $8.501 million in the same 2025 period.
Net cash used in operating activities $9.567 million Nine months ended September 30, 2026; $6.525 million in the same 2025 period.
Cash and cash equivalents $1.342 million Balance as of September 30, 2026.
Private placement consideration Up to approximately $45.6 million Private placement agreed to on November 15, 2026; initial contemplated closing approximately $15.6 million, subject to stated conditions.
Secured note initial tranche $650,000 Funded November 9, 2026; outstanding amounts accrue 10% annual interest. Total principal financing is up to $1.5 million.
Restricted stock units granted 17,700,000 RSUs Granted November 12, 2026, to executives, directors, advisors and employees.
Annualized recurring revenues (ARR) financial
"Cyabra uses annualized recurring revenues (ARR) as a performance metric"
Annualized recurring revenues (ARR) is the yearly value of a company’s predictable, subscription-style income based on current contracts or customers, calculated by converting recurring payments into a 12-month run rate and excluding one-time charges. Investors use ARR like a landlord uses projected annual rent: it reveals how much steady cash the business can expect, how fast that base is growing or shrinking, and helps assess company stability, valuation, and sensitivity to customer loss.
Adjusted EBITDA financial
"Adjusted EBITDA, as a non-GAAP measure, is useful in evaluating our operating performance"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
going concern financial
"substantial doubt exists about our ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
reverse recapitalization financial
"The Merger Agreement was accounted for as a reverse recapitalization"
A reverse recapitalization is a way for a privately held company to become publicly traded by taking control of an existing public company and swapping ownership rather than going through a traditional public offering. For investors it matters because it can quickly change who controls a company and reshape its share structure and value — like a homeowner swapping houses and keys rather than building a new one — so it can create sudden shifts in stock supply, dilution and market expectations.
pre-funded warrants financial
"pre-funded warrants to purchase 25,006,895 shares of common stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Level 3 measurement financial
"represents a Level 3 measurement within the fair value hierarchy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were CYAB’s revenue and net loss for the first nine months of 2026?

Revenue was $5.271 million and net loss was $16.801 million for the nine months ended September 30, 2026. The corresponding 2025 figures were $4.078 million in revenue and $8.501 million in net loss.

What conditions apply to CYAB’s proposed private placement?

The contemplated initial closing of approximately $15.6 million requires stockholder approvals and Nasdaq confirmation that listing deficiencies have been cured and continued listing approved. It had not occurred as of the interim statements’ issuance; the agreement also provides for potential additional investments of up to $30 million over three years.

When is CYAB’s secured note due, and can it be extended?

The $650,000 initial tranche funded on November 9, 2026, accrues interest at 10% per annum and is due January 15, 2027. The lender may extend maturity in three-month increments until December 31, 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
http://fasb.org/srt/2026#ChiefExecutiveOfficerMember 1 false 0002032341 --12-31 Q3 P5Y P12M 0002032341 us-gaap:SubsequentEventMember us-gaap:SeriesDPreferredStockMember 2026-11-15 0002032341 us-gaap:SubsequentEventMember 2026-11-15 0002032341 us-gaap:SeriesDPreferredStockMember 2026-11-15 0002032341 2026-11-15 0002032341 us-gaap:SubsequentEventMember 2026-11-12 0002032341 2025-01-01 2025-12-31 0002032341 2026-01-01 2026-09-30 0002032341 srt:ProFormaMember 2025-07-01 2025-09-30 0002032341 srt:ProFormaMember 2026-07-01 2026-09-30 0002032341 srt:ProFormaMember 2025-01-01 2025-09-30 0002032341 srt:ProFormaMember 2026-01-01 2026-09-30 0002032341 2026-11-09 0002032341 cyab:AlphaCapitalMember 2026-11-09 0002032341 cyab:SeriesBCommonWarrantSharesMember us-gaap:CommonStockMember 2026-07-09 2026-07-09 0002032341 cyab:SeriesAPreferredSharesAndSeriesBConvertiblePreferredStockMember 2026-07-09 2026-07-09 0002032341 us-gaap:SeriesCPreferredStockMember 2026-07-09 0002032341 srt:DirectorMember 2026-01-01 2026-09-30 0002032341 srt:MinimumMember cyab:Pre-FundedWarrantSharesMember 2026-09-30 0002032341 cyab:SeriesBCommonWarrantSharesMember 2026-07-09 2026-07-09 0002032341 srt:MaximumMember cyab:Pre-FundedWarrantSharesMember 2026-09-30 0002032341 cyab:SeriesACommonWarrantsMember 2026-07-09 2026-07-09 0002032341 cyab:Pre-FundedWarrantSharesMember 2026-07-09 2026-07-09 0002032341 cyab:PreFundedWarrantsMember 2026-07-09 2026-07-09 0002032341 cyab:PurchaseAgreementMember cyab:PreFundedWarrantsMember 2026-07-09 2026-07-09 0002032341 cyab:PurchaseAgreementMember 2026-07-09 0002032341 cyab:PurchaseAgreementMember 2026-07-09 2026-07-09 0002032341 cyab:PromissoryNoteMember cyab:AlphaCapitalAnstaltMember 2026-03-13 0002032341 cyab:PromissoryNoteMember cyab:AlphaCapitalAnstaltMember 2026-03-09 0002032341 cyab:BridgeLoanFromBankMember 2026-03-02 0002032341 cyab:BridgeLoanFromBankMember 2026-01-14 0002032341 cyab:PromissoryNoteMember cyab:AlphaCapitalAnstaltMember 2026-02-05 0002032341 cyab:PromissoryNoteMember cyab:AlphaCapitalAnstaltMember 2026-01-08 0002032341 cyab:BeyondOneYearMember 2026-09-30 0002032341 cyab:WithinOneYearMember 2026-09-30 0002032341 2026-09-30 0002032341 2025-12-31 0002032341 srt:ChiefOperatingOfficerMember 2025-09-30 0002032341 srt:ChiefOperatingOfficerMember 2026-09-30 0002032341 srt:ChiefOperatingOfficerMember 2025-07-01 2025-09-30 0002032341 srt:ChiefOperatingOfficerMember 2026-07-01 2026-09-30 0002032341 srt:ChiefOperatingOfficerMember 2025-01-01 2025-09-30 0002032341 srt:ChiefOperatingOfficerMember 2026-01-01 2026-09-30 0002032341 2025-09-30 0002032341 2025-07-01 2025-09-30 0002032341 2025-01-01 2025-09-30 0002032341 2026-07-01 2026-09-30 0002032341 us-gaap:MeasurementInputSharePriceMember 2026-09-30 0002032341 us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2026-09-30 0002032341 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2026-09-30 0002032341 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2026-01-01 2026-09-30 0002032341 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2026-01-01 2026-09-30 0002032341 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2026-01-01 2026-09-30 0002032341 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2026-01-01 2026-09-30 0002032341 us-gaap:MeasurementInputOptionVolatilityMember srt:MaximumMember 2026-01-01 2026-09-30 0002032341 us-gaap:MeasurementInputOptionVolatilityMember srt:MinimumMember 2026-01-01 2026-09-30 0002032341 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0002032341 us-gaap:RestrictedStockUnitsRSUMember 2026-08-13 2026-08-13 0002032341 us-gaap:RestrictedStockUnitsRSUMember 2026-05-14 2026-05-14 0002032341 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2026-03-27 2026-03-27 0002032341 us-gaap:EmployeeStockOptionMember cyab:TwentyTwentyShareOptionPlanMember 2026-02-10 2026-02-10 0002032341 us-gaap:GeneralAndAdministrativeExpense 2025-07-01 2025-09-30 0002032341 us-gaap:GeneralAndAdministrativeExpense 2026-07-01 2026-09-30 0002032341 us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0002032341 us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0002032341 us-gaap:SellingAndMarketingExpense 2025-07-01 2025-09-30 0002032341 us-gaap:SellingAndMarketingExpense 2026-07-01 2026-09-30 0002032341 us-gaap:SellingAndMarketingExpense 2025-01-01 2025-09-30 0002032341 us-gaap:SellingAndMarketingExpense 2026-01-01 2026-09-30 0002032341 us-gaap:ResearchAndDevelopmentExpense 2025-07-01 2025-09-30 0002032341 us-gaap:ResearchAndDevelopmentExpense 2026-07-01 2026-09-30 0002032341 us-gaap:ResearchAndDevelopmentExpense 2025-01-01 2025-09-30 0002032341 us-gaap:ResearchAndDevelopmentExpense 2026-01-01 2026-09-30 0002032341 srt:MinimumMember 2026-09-30 0002032341 srt:MaximumMember 2026-09-30 0002032341 cyab:SeriesBCommonWarrantsMember 2026-09-09 0002032341 cyab:SeriesACommonWarrantsMember 2026-09-09 0002032341 us-gaap:SeriesCPreferredStockMember cyab:PreFundedWarrantsMember 2026-09-09 0002032341 us-gaap:SeriesCPreferredStockMember 2026-09-09 0002032341 cyab:PreFundedWarrantsMember 2026-09-30 0002032341 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0002032341 us-gaap:SeriesBPreferredStockMember 2026-09-30 0002032341 us-gaap:SeriesAPreferredStockMember 2026-09-30 0002032341 2026-09-03 0002032341 cyab:SeriesABAndCPreferredSharesMember 2026-09-30 0002032341 us-gaap:FairValueInputsLevel3Member cyab:PIPEWarrantMember 2026-07-01 2026-09-30 0002032341 us-gaap:FairValueInputsLevel3Member cyab:PIPEWarrantMember 2026-06-30 0002032341 us-gaap:FairValueInputsLevel3Member cyab:PIPEWarrantMember 2026-04-01 2026-06-30 0002032341 us-gaap:FairValueInputsLevel3Member cyab:PIPEWarrantMember 2026-03-31 0002032341 us-gaap:FairValueInputsLevel3Member cyab:PIPEWarrantMember 2026-03-27 2026-03-31 0002032341 us-gaap:FairValueInputsLevel3Member cyab:PIPEWarrantMember 2026-03-26 0002032341 us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0002032341 us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0002032341 cyab:TwoThousandTwentyFourConvertibleNoteLiabilityMember 2026-01-01 2026-09-30 0002032341 cyab:TwoThousandTwentyFourConvertibleNoteLiabilityMember 2025-12-31 0002032341 cyab:TwoThousandTwentyFourConvertibleNotesMember 2026-01-01 2026-09-30 0002032341 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0002032341 us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0002032341 us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0002032341 us-gaap:ConvertibleNotesPayableMember 2026-09-30 0002032341 us-gaap:ConvertibleNotesPayableMember 2025-12-31 0002032341 cyab:SponsorMember 2025-02-28 0002032341 2024-12-31 2024-12-31 0002032341 2024-07-22 0002032341 cyab:TwoThousandTwentyFourConvertibleNotesMember cyab:LegacyCyabraMember 2024-07-22 0002032341 us-gaap:ConvertibleNotesPayableMember 2024-07-22 0002032341 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-09-30 0002032341 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0002032341 us-gaap:IPOMember 2025-12-31 0002032341 cyab:MergerAndAcquisitionScenarioMember 2025-12-31 0002032341 2022-05-31 0002032341 us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0002032341 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0002032341 us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0002032341 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0002032341 cyab:PIPEFinancingMember 2026-01-01 2026-09-30 0002032341 cyab:PreferredClassCMember 2025-12-04 2025-12-04 0002032341 us-gaap:PreferredClassBMember 2025-12-04 2025-12-04 0002032341 2025-12-04 2025-12-04 0002032341 cyab:PromissoryNoteMember 2025-12-04 0002032341 us-gaap:SubsequentEventMember 2026-10-31 0002032341 cyab:LowensteinSandlerLLPMember 2026-07-01 2026-09-30 0002032341 cyab:LowensteinSandlerLLPMember 2026-01-01 2026-09-30 0002032341 cyab:LowensteinSandlerLLPMember 2025-12-18 2025-12-18 0002032341 cyab:LoebLoebLLPMember 2025-12-18 2025-12-18 0002032341 cyab:LadenburgMember 2026-06-29 0002032341 cyab:LadenburgMember 2025-10-28 2025-10-28 0002032341 cyab:LifeSciCapitalLLCMember 2026-06-29 0002032341 cyab:UnderwritersArrangementsMember 2026-10-28 0002032341 cyab:UnderwritersArrangementsMember cyab:LifeSciCapitalLLCMember 2025-10-28 2025-10-28 0002032341 cyab:LifeSciCapitalLLCMember 2025-10-28 2025-10-28 0002032341 cyab:UnderwritersArrangementsMember 2025-10-28 2025-10-28 0002032341 cyab:LegacyCyabraMember 2026-09-30 0002032341 2026-03-27 0002032341 us-gaap:RestrictedStockUnitsRSUMember 2026-03-27 0002032341 srt:MinimumMember 2025-11-06 0002032341 srt:MaximumMember 2025-11-06 0002032341 cyab:LegacyCyabraMember 2024-07-22 0002032341 2024-12-31 0002032341 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0002032341 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0002032341 us-gaap:CommonStockMember 2025-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:RedeemablePreferredStockMember 2025-09-30 0002032341 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0002032341 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0002032341 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0002032341 2025-06-30 0002032341 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0002032341 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0002032341 us-gaap:CommonStockMember 2025-06-30 0002032341 us-gaap:PreferredStockMember us-gaap:RedeemablePreferredStockMember 2025-06-30 0002032341 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-09-30 0002032341 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0002032341 us-gaap:CommonStockMember 2026-09-30 0002032341 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-07-01 2026-09-30 0002032341 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-07-01 2026-09-30 0002032341 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-07-01 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-07-01 2026-09-30 0002032341 2026-06-30 0002032341 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0002032341 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0002032341 us-gaap:CommonStockMember 2026-06-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-06-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-06-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-06-30 0002032341 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-09-30 0002032341 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0002032341 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:RedeemablePreferredStockMember 2025-01-01 2025-09-30 0002032341 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0002032341 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0002032341 us-gaap:CommonStockMember 2024-12-31 0002032341 us-gaap:PreferredStockMember us-gaap:RedeemablePreferredStockMember 2024-12-31 0002032341 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-09-30 0002032341 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-01-01 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-01-01 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:RedeemablePreferredStockMember 2026-01-01 2026-09-30 0002032341 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0002032341 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0002032341 us-gaap:CommonStockMember 2025-12-31 0002032341 us-gaap:PreferredStockMember us-gaap:RedeemablePreferredStockMember 2025-12-31 0002032341 us-gaap:CommonClassAMember 2025-12-31 0002032341 us-gaap:CommonClassAMember 2026-09-30 0002032341 us-gaap:RedeemableConvertiblePreferredStockMember 2025-12-31 0002032341 cyab:RedeemableConvertiblePreferredCAndC1SharesMember 2025-12-31 0002032341 cyab:RedeemableConvertiblePreferredCAndC1SharesMember 2026-09-30 0002032341 cyab:RedeemablePreferredA2AndA3SharesMember 2025-12-31 0002032341 cyab:RedeemablePreferredA2AndA3SharesMember 2026-09-30 0002032341 cyab:RedeemablePreferredAAndA1SharesMember 2025-12-31 0002032341 cyab:RedeemablePreferredAAndA1SharesMember 2026-09-30 0002032341 2026-11-12 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-01-01 2025-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:RedeemablePreferredStockMember 2026-07-01 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:RedeemablePreferredStockMember 2025-07-01 2025-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-07-01 2025-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-07-01 2025-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-07-01 2025-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-09-30 0002032341 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0002032341 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-09-30 0002032341 us-gaap:RedeemableConvertiblePreferredStockMember 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-12-31 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-12-31 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-12-31 0002032341 us-gaap:PreferredStockMember us-gaap:RedeemablePreferredStockMember 2026-09-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-12-31 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-12-31 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2024-12-31 0002032341 us-gaap:PreferredStockMember us-gaap:RedeemablePreferredStockMember 2026-06-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-06-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-06-30 0002032341 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-06-30 0002032341 us-gaap:RedeemablePreferredStockMember 2026-07-01 2026-09-30 0002032341 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0002032341 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0002032341 us-gaap:MeasurementInputExpectedDividendRateMember 2025-12-31 0002032341 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0002032341 cyab:TwoThousandTwentyFourConvertibleNoteLiabilityMember 2026-09-30 0002032341 2026-09-09 0002032341 cyab:SeriesACommonWarrantsMember 2026-09-30 0002032341 cyab:SeriesBCommonWarrantsMember 2026-09-30 0002032341 us-gaap:MeasurementInputExpectedDividendRateMember 2026-01-01 2026-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:ILS xbrli:shares cyab:Segments

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q 

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

 

For the quarterly period ended September 30, 2026 

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

 

For the transition period from ____ to ____

 

Commission file number: 001-43214 

 

Cyabra, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   99-4210757
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)
     
13 Gershon Shatz
Tel Aviv, Israel
  6997543
(Address of principal executive offices)   (Zip Code)

 

+972-54-768-8642
(Registrant’s telephone number, including area code)

 

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   CYAB   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
   
Non-accelerated filer ☒ Smaller reporting company ☒
   
  Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

As of November 12, 2026, the number of outstanding shares of the registrant’s common stock, par value $0.0001 per share, was 38,399,374.

 

 

 

 

 

 

CYABRA, INC.

FORM 10-Q TABLE OF CONTENTS

 

    Page
Part I Financial Information 1
Item 1. Financial Statements (unaudited) 1
  Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 F-2
  Condensed Consolidated Statements of Operations for the nine months ended September 30, 2026 and 2025 F-3
  Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2026 and 2025 F-4
  Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 F-6
  Notes to Condensed Consolidated Financial Statements F-7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 2
Item 3. Quantitative and Qualitative Disclosures About Market Risk 16
Item 4. Controls and Procedures 16
     
Part II Other Information 17
Item 1. Legal Proceedings 17
Item 1A. Risk Factors 17
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 18
Item 3. Defaults Upon Senior Securities 18
Item 4. Mine Safety Disclosures 18
Item 5. Other Information 18
Item 6. Exhibits 19

 

i

 

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

 

Cyabra, Inc.

 

Condensed Consolidated

Interim

Financial Statements

September 30, 2026

 

1

 

 

Cyabra, Inc.

 

and its subsidiaries

 

Condensed Consolidated Interim Financial Statements as of September 30, 2026 (Unaudited)

 

Contents

 

    PAGE
Condensed Consolidated Interim Balance Sheets   F-2
Condensed Consolidated Interim Statements of Operations   F-3
Condensed Consolidated Interim Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency   F-4
Condensed Consolidated Interim Statements of Cash Flows   F-6
Notes to Condensed Consolidated Interim Financial Statements   F-7

 

F-1

 

 

Condensed Consolidated Interim Balance Sheets (Unaudited)

U.S. dollars in thousands (except share data)

 

    September 30,
2026
    December 31,
2025
 
Assets            
Current assets            
Cash and cash equivalents   $ 1,342     $ 294  
Restricted cash     23       22  
Accounts receivable     433       269  
Other current assets     603       152  
Total current assets     2,401       737  
                 
Non-Current Assets                
Operating right-of-use asset     325       575  
Property and equipment, net     141       146  
Other assets     94       -  
Total non-current assets     560       721  
Total Assets     2,961       1,458  
                 
Liabilities, Redeemable Convertible Preferred Shares and Capital Deficiency                
Current liabilities                
Trade accounts payable     1,054       1,775  
Accrued expenses     1,487       476  
Short term loans     1,869       5,768  
Operating lease liability     355       380  
Deferred revenues     2,779       2,816  
Employees and related     2,076       1,298  
Other current liabilities     1,254       94  
Convertible notes     -       12,869  
Liability with respect to warrants     14       -  
Total current liabilities     10,888       25,476  
                 
Non-Current Liabilities                
Operating lease liability     23       268  
Long-term deferred revenues     586       115  
Liability with respect to warrants     -       370  
Total non-current liabilities     609       753  
Total liabilities     11,497       26,229  
                 
Commitments and contingent liabilities                
                 
Redeemable Convertible Preferred Shares:                
Redeemable Preferred A and A-1 shares, NIS 0.01 par value: 0 and 607,373 shares authorized as of September 30, 2026 and December 31, 2025, respectively, 0 and 515,186 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively. Aggregate liquidation preference of $0 and $7,180 as of September 30, 2026 and December 31, 2025, respectively; Redeemable Preferred A-2 and A-3 shares, NIS 0.01 par value: 0 and 596,056 shares authorized as of September 30, 2026 and December 31, 2025, respectively, and 0 and 388,739 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively. Aggregate liquidation preference of $0 and $6,554 as of September 30, 2026 and December 31, 2025, respectively. Redeemable Convertible Preferred C and C-1 shares, NIS 0.01 par value: 0 and 803,963 shares authorized as of September 30, 2026 and December 31, 2025, respectively, and 0 and 233,001 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively. Aggregate liquidation preference of $0 and $3,446 as of September 30, 2026 and December 31, 2025, respectively.     -       15,268  
                 
Capital Deficiency:                
Class A common stock     4       2  
Additional paid-in capital     55,634       7,332  
Accumulated deficit     (64,174 )     (47,373 )
Total capital deficiency     (8,536 )     (40,039 )
Total liabilities, redeemable convertible preferred shares and capital deficiency   $ 2,961     $ 1,458  

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

F-2

 

 

Condensed Consolidated Interim Statements of Operations (Unaudited)

 

U.S. dollars in thousands (except per share data)

 

    For the Nine Months Ended
September 30,
    For the Three Months Ended
September 30,
 
    2026     2025     2026     2025  
Revenues     5,271       4,078       2,003       1,487  
Cost of revenues     800       584       304       175  
Gross profit     4,471       3,494       1,699       1,312  
                                 
Operating costs and expenses                                
Research and development expenses     9,742       5,347       2,174       1,657  
Sales and marketing expenses     3,991       4,443       1,432       1,250  
General and administrative expenses     8,899       3,319       1,310       563  
Total operating loss     (18,161 )     (9,615 )     (3,217 )     (2,158 )
                                 
Finance income (expenses), net     794       1,134       (5 )     (582 )
Other income (expenses)     631       -       631       -  
Loss before income taxes     (16,736 )     (8,481 )     (2,591 )     (2,740 )
Income tax expense     65       20       1       1  
Net loss for the period     (16,801 )     (8,501 )     (2,592 )     (2,741 )
                                 
Loss per share attributable to common shareholders                                
Basic and diluted loss per share     (1.00 )     (3.58 )     (0.13 )     (1.07 )
                                 
Weighted average number of common stock outstanding used in computation of basic and diluted loss per share     19,413,724       2,511,059       41,077,186       2,737,168  

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

F-3

 

 

Condensed Consolidated Interim Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency (Unaudited)

 

    Redeemable
Preferred
                                  Additional              
    A, A1,A2,A3,
C and C-1 Shares
    Series A
Preferred Stock
    Series B
Preferred Stock
    Series C
Preferred Stock
    Common Stock     paid in
capital
    Accumulated
deficit
    Total  
    Shares     USD
thousands
    Shares     USD
thousands
    Shares     USD
thousands
    Shares     USD
thousands
    Shares     USD
thousands
    USD
thousands
    USD
thousands
    USD
thousands
 
Balance at December 31, 2025     1,136,926       15,268       -       -       -       -       -       -       3,019,557       2       7,332       (47,373 )     (40,039 )
                                                                                                         
Conversion of redeemable preferred shares     (1,136,926 )     (15,268 )     -       -       -       -       -       -       4,103,962        *-       15,268       -       15,268  
Exercise of stock options and warrants     -       -       -       -       -       -       -       -       49,044       *-       3       -       3  
Shares issued in connection with loan agreement     -       -       -       -       -       -       -       -       2,751       *-       -       -       *-  
Impact of closing of Business Combination     -       -       -       -       5,330       *-       10,660       *-       4,178,485        *-       (1,564 )     -       (1,564 )
Shares issued to advisors     -       -       -       -       -       -       -       -       1,630,000        *-       4,277       -       4,277  
Conversion of convertible notes     -       -       3,061       *-       -       -       -       -       1,356,459        *-       12,676       -       12,676  
Issuance of the private investment into public equity (“PIPE”) shares and warrants     -       -       -       -       8,000       *-       -       -       1,175,090       *-       12,116       -       12,116  
Conversion of Series A Preferred Stock into common stock     -       -       (884 )     *-       -       -       -       -       250,024       *-       *-       -       -  
Reclassification of warrant to equity     -       -       -       -       -       -       -       -       -       -       390       -       390  
Conversion of Series B Preferred Stock into common stock     -       -       -       -       (385 )     *-       -       -       263,699       *-       *-       -       -  
Exercise of pre-funded warrants     -       -       -       -       -       -       -       -       7,181,217       1       -       -       1  
RSU (as defined below) vesting     -       -       -       -       -       -       -       -       318,000       *-       *-       -       -  
Conversion of Series A Preferred Stock and Series B Preferred Stock into common stock and pre-funded warrants     -       -       (2,177 )     *-       (12,945 )     *-       -       -       9,756,323       1       (1 )     -       -  
Exchange of Series C Preferred Stock     -       -       -       -       -       -       (10,660 )     *-       -       -       *-       -       -  
Share-based payments     -       -       -       -       -       -       -       -       -       -       5,137       -       5,137  
Net loss     -       -       -       -       -       -       -       -       -       -       -       (16,801 )     (16,801 )
Balance at September 30, 2026     -       -       -       -       -       -       -       -       33,284,611       4       55,634       (64,174 )     (8,536 )

 

    Redeemable
Preferred
                                  Additional              
    A, A1,A2,A3,
C and C-1 Shares
    Series A
Preferred Stock
    Series B
Preferred Stock
    Series C
Preferred Stock
    Common Stock     paid in
capital
    Accumulated
deficit
    Total  
    Shares     USD
thousands
    Shares     USD
thousands
    Shares     USD
thousands
    Shares     USD
thousands
    Shares     USD
thousands
    USD
thousands
    USD
thousands
    USD
thousands
 
Balance at December 31, 2024     903,925       11,780       -       -       -       -       -       -       2,351,976       2       4,132       (34,554 )     (30,420 )
Issuance of Series C Preferred Stock, net     165,633       2,431       -       -       -       -       -       -       -       -       -       -       -  
Issuance of shares     -       -       -       -       -       -       -       -       20,601       *-       *-       -       *-  
Equity instrument issued with debt     -       -       -       -       -       -       -       -       -       -       124       -       124  
Conversion of SAFE (as defined below) to Series C-1 Preferred Stock     67,368       1,057       -       -       -       -       -       -       -       -       -       -       -  
Share-based payments     -       -       -       -       -       -       -       -       -       -       2,703       -       2,703  
Exercise of options     -       -       -       -       -       -       -       -       630,791       *-       3       -       3  
Net loss     -       -       -       -       -       -       -       -       -       -       -       (8,501 )     (8,501 )
Balance at September 30, 2025     1,136,926       15,268       -       -       -       -       -       -       3,003,368       2       6,962       (43,055 )     (36,091 )

 

F-4

 

 

    Redeemable
Preferred
                                  Additional              
    A, A1,A2,A3,
C and C-1 Shares
    Series A
Preferred Stock
    Series B
Preferred Stock
    Series C
Preferred Stock
    Common Stock     paid in
capital
    Accumulated
deficit
    Total  
    Shares     USD
thousands
    Shares     USD
thousands
    Shares     USD
thousands
    Shares     USD
thousands
    Shares     USD
thousands
    USD
thousands
    USD
thousands
    USD
thousands
 
Balance at June 30, 2026        -          -       2,177       *-       13,330       *-       10,660       *-       14,590,282       2       49,584       (61,582 )     (11,996 )
Issuance of PIPE shares and warrants     -       -       -       -       -       -       -       -       1,175,090       *-       5,345       -       5,345  
Conversion of Series B Preferred Stock into common stock     -       -       -       -       (385 )     *-       -       -       263,699       *-       *-       -       -  
Exercise of pre-funded warrants     -       -       -       -       -       -       -       -       7,181,217       1       -       -       1  
RSU vesting     -       -       -       -       -       -       -       -       318,000       *-       *-       -       -  
Conversion of Series A Preferred Stock and Series B Preferred Stock into common stock and pre-funded warrants     -       -       (2,177 )     *-       (12,945 )     *-       -       -       9,756,323       1       (1 )     -       -  
Exchange of Series C Preferred Stock     -       -       -       -       -       -       (10,660 )     *-       -       -       *-       -       -  
Share-based payments     -       -       -       -       -       -       -       -       -       -       706       -       706  
Net loss     -       -       -       -       -       -       -       -       -       -       -       (2,592 )     (2,592 )
Balance at September 30, 2026     -       -       -       -       -       -       -       -       33,284,611       4       55,634       (64,174 )     (8,536 )

 

    Redeemable
Preferred
                                  Additional              
    A, A1,A2,A3,
C and C-1 Shares
    Series A
Preferred Stock
    Series B
Preferred Stock
    Series C
Preferred Stock
    Common Stock     paid in
capital
    Accumulated
deficit
    Total  
    Shares     USD
thousands
    Shares     USD
thousands
    Shares     USD
thousands
    Shares     USD
thousands
    Shares     USD
thousands
    USD
thousands
    USD
thousands
    USD
thousands
 
Balance at June 30, 2025     1,136,926       15,268       -       -       -       -       -       -       2,542,384       2       6,389       (40,314 )     (33,923 )
Issuance of shares     -       -       -       -       -       -       -       -       20,601       *-       *-       -       *-  
Equity instrument issued with debt     -       -       -       -       -       -       -       -       -       -       124       -       124  
Share-based payments     -       -       -       -       -       -       -       -       -       -       448       -       448  
Exercise of options     -       -       -       -       -       -       -       -       440,383       *-       1       -       1  
Net loss     -       -       -       -       -       -       -       -       -       -       -       (2,741 )     (2,741 )
Balance at September 30, 2025     1,136,926       15,268       -       -       -       -       -       -       3,003,368       2       6,962       (43,055 )     (36,091 )

 

* Less than $1 thousand

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

F-5

 

 

Condensed Consolidated Interim Statements of Cash Flows (Unaudited)

 

    Nine Months Ended  
    September 30,  
    2026     2025  
    USD     USD  
    thousands     thousands  
Cash flows – operating activities            
Net loss for the period   $ (16,801 )   $ (8,501 )
Adjustments:                
Depreciation     46       42  
Interest expense     191       162  
Payment of previously accrued interest     (126 )     -  
Share-based payments     5,137       2,703  
Share-based payments for advisory services     1,009       -  
Shares issued to advisors     2,100       -  
Gain on settlement of accounts payable     (631 )     -  
Exchange rate differences     63       (20 )
Change in fair value of financial liabilities     (1,388 )     (1,507 )
Changes in operating assets and liabilities:                
Increase in other assets     (355 )     (56 )
Increase in accounts receivable     (164 )     (150 )
Increase in trade accounts payable     499       644  
Change in ROU asset and lease liability     (20 )     35  
Increase in deferred revenues     434       75  
Increase in employees and related     778       278  
Decrease in other current liabilities     (339 )     (230 )
Net cash used in operating activities     (9,567 )     (6,525 )
                 
Cash flows – investing activities                
Purchase of property and equipment     (42 )     (48 )
Sale of property and equipment     1       1  
Net cash used in investing activity     (41 )     (47 )
                 
Cash flows – financing activities                
Bank overdraft     -       43  
Receipt of loans     2,655       4,613  
Repayment of loans     (6,630 )     (1,463 )
Exercise of options     3       3  
Exercise of pre-funded warrants     1       -  
Cash received from Merger Agreement upon the effectiveness of the Business Combination     1,336       -  
Proceeds from PIPE, net of transaction costs     13,345       -  
Issuance of preferred shares, net     -       2,431  
Net cash provided by financing activities     10,710       5,627  
                 
Increase (decrease) in cash, cash equivalents and restricted cash     1,102       (945 )
Exchange rate differences on cash and cash equivalents and restricted cash     (53 )     20  
Cash, cash equivalents and restricted cash at the beginning of period     316       946  
Cash, cash equivalents and restricted cash at the end of the period     1,365       21  
                 
Supplemental Disclosures of cash flow information:                
Interest paid   $ 251     $ 77  
Supplemental disclosure of non-cash activity:                
Conversion of redeemable preferred shares   $ 15,268     $ -  
Conversion of convertible notes   $ 12,676     $ -  
Conversion of warrant liability to equity   $ 390     $ -  
Shares issued to advisors     2,112       -  
Right of use asset recognized with corresponding lease liability   $ -     $ 296  
Conversion of SAFE   $ -     $ 1,057  
                 
Cash, cash equivalents and restricted cash at the end of the period:                
Cash and cash equivalents   $ 1,342     $ -  
Restricted cash   $ 23     $ 21  

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

F-6

 

 

Notes to Condensed Consolidated Interim Financial Statements (Unaudited)

 

Note 1 — General

 

A. Cyabra, Inc. (the “Company”) is a newly formed entity that was formed for the purpose of effecting the Merger Agreement (see below) and now serves as a publicly-traded company. Its wholly owned subsidiary is Cyabra Strategy Ltd. (“Legacy Cyabra”), an Israeli limited company.

 

From its formation until the consummation of the Merger Agreement on March 27, 2026, the Company had no operations and was formed solely for the purpose of consummating the transactions contemplated by the Merger Agreement. Legacy Cyabra, as the accounting acquirer under the Merger Agreement and the predecessor entity to the Company for financial reporting purposes, had active operations before the consummation of the Merger Agreement. Consequently, these financial statements reflect the financial results of Legacy Cyabra (as the predecessor entity to the Company) until March 27, 2026, and those of the Company (as the combined company following the Merger Agreement) from that date forward.

 

B. The Company operates as a single operating segment and addresses the threat of fake news for brands and the public sector and provide software that identifies bad actors online, and mitigates the threat in real-time.

 

On March 12, 2020, Legacy Cyabra established a wholly owned U.S. subsidiary Cyabra Strategy Inc. (the “subsidiary”), for marketing and distribution activity. The subsidiary commenced operations during 2020.

 

Since October 2023, Israel has been involved in significant military conflicts with Hamas and Hezbollah. In February 2026, hostilities escalated significantly into a direct military conflict involving Israel, the United States, and Iran. While a ceasefire between Israel and Hamas remains largely in effect following the October 2025 agreements, the subsequent outbreak of the conflict with Iran has introduced renewed volatility and uncertainty into the region. Although a partial two-week ceasefire regarding direct regional operations was announced on April 7, 2026, and subsequently extended, the security situation remains fluid.

 

The Company estimates that based on information available as of the date these financial statements are issued, the ongoing regional conflicts have not had a material impact on its results of operations to date. Since these events are beyond the control of the Company, and factors such as the resumption or escalation of hostilities or their cessation may affect the Company’s estimates, the Company is currently unable to reasonably estimate the extent of the impact on its business activities and results of operations in the medium and long term. The Company continues to regularly monitor the developments on the subject and examines the consequences for its activities and the value of its assets.

 

C. Reverse Recapitalization: On July 22, 2024, Legacy Cyabra entered into a merger agreement (the “Merger Agreement”) with Trailblazer Merger Corporation I (“Parent”), a blank-check special purpose acquisition company, Trailblazer Merger Sub, Ltd., a direct, wholly owned subsidiary of Parent (“Merger Sub”), and Trailblazer Holdings, Inc., a direct, wholly owned subsidiary of Parent (“Holdings”). The Merger Agreement contemplated (a) the merger of Parent with and into Holdings, with Holdings surviving, and (b) the merger of Merger Sub with and into Legacy Cyabra, with Legacy Cyabra surviving as a wholly owned subsidiary of Holdings. The transactions were completed on March 27, 2026, as described below. 

 

The aggregate merger consideration originally contemplated to be received by Legacy Cyabra’s shareholders was 7,000,000 shares of Holdings common stock, par value $0.0001 per share (the “Holdings Common Stock”), calculated by dividing (a) $70,000,000 by (b) $10.00 (the “Aggregate Merger Consideration”). On November 6, 2025, Legacy Cyabra entered into an amendment to the Merger Agreement, pursuant to which the Aggregate Merger Consideration was changed to $106,000,000 instead of $70,000,000.

 

On March 27, 2026, the parties completed the Merger Agreement pursuant to which Holdings merged with Parent, with Holdings continuing as the surviving company of such merger and Merger Sub merged with Legacy Cyabra, with Legacy Cyabra continuing as the surviving company of such merger and a wholly-owned subsidiary of Holdings (the “Merger”). Upon the Closing, three key employees of the Company received 400,000 restricted stock units (“RSUs”) of the Company in the aggregate, and are entitled to a one time transaction bonus of $400,000 each. 

 

F-7

 

 

Upon the effectiveness of the Merger, each outstanding Parent Class A common stock and the sole outstanding Parent Class B common stock was converted into a common share of Holdings on a one-for-one basis. Upon the effectiveness of the Merger, each outstanding ordinary share of Legacy Cyabra was converted into 3.6097 common share of Holdings (the “Conversion Ratio”). Each outstanding Legacy Cyabra warrant and option to purchase one Legacy Cyabra share, was to become exercisable for such number of Holdings common shares as were equal to the Conversion Ratio. The exercise price per Holdings common share of each such converted Legacy Cyabra option and warrant was to be adjusted based on dividing the existing per share exercise price by the Conversion Ratio. The terms of vesting, exercise and/or settlement, as applicable, of such converted options and warrants were to remain the same following such conversion.

 

Immediately prior to the closing, seven directors were elected to Holdings’ board of directors.

 

In connection with the closing of the Merger Agreement, the shares of common stock of Holdings are now listed on the Nasdaq Global Market and began trading under the symbol “CYAB”.

 

The Merger Agreement was accounted for as a reverse recapitalization in accordance with U.S. generally accepted accounting principles (“GAAP”). Under this method of accounting, Legacy Cyabra was treated as the accounting acquirer and the Parent was treated as the “acquired” company for financial reporting purposes. Legacy Cyabra was determined to be the accounting acquirer based on evaluation of the following facts and circumstances:

 

  ● Legacy Cyabra’s shareholders were to hold approximately 61.8% of the outstanding common stock in Holdings upon the closing of the Merger Agreement;

 

  ● Legacy Cyabra’s senior management were to comprise the senior management of Holdings;

 

  ● The directors nominated by Legacy Cyabra were to constitute a majority of the board of directors of Holdings (six out of seven of the initial directors);

 

  ● Legacy Cyabra’s operations were to comprise the ongoing operations of Holdings; and

 

  ● Legacy Cyabra’s name was to be the name used by Holdings – Cyabra Inc. (in replacement of Trailblazer Holdings, Inc).

 

Under the reverse recapitalization accounting method, the Merger Agreement was deemed to be the equivalent of a capital transaction in which Legacy Cyabra issued shares for the net assets of the Parent. The net assets of the Parent were stated at fair value, with no goodwill or other intangible assets recorded. Operations prior to the Merger Agreement are those of Legacy Cyabra.

 

In accordance with the applicable guidance to reverse recapitalization, the equity structure has been retroactively adjusted in all comparative periods up to the date of the Closing (the “Closing Date”), to reflect the number of Holdings’ common stock issued to Legacy Cyabra shareholders in connection with the reverse recapitalization transaction. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Cyabra shareholders prior to the reverse recapitalization have been retroactively restated as shares reflecting the Conversion ratio established pursuant to the Merger Agreement. In conjunction with the reverse recapitalization, each outstanding Legacy Cyabra ordinary share was converted into 3.6097 shares of Holdings common stock.

 

Underwriters Arrangements

 

On October 28, 2025, Trailblazer, Holdings, Legacy Cyabra, LifeSci (as defined below) and Ladenburg Thalmann & Co. Inc. (“Ladenburg” and together with LifeSci, the “Underwriters”) agreed that, in lieu of the payment in cash of certain deferred underwriting commissions owed to the Underwriters in connection with the initial public offering (“IPO”), Holdings would issue to the Underwriters 207,000 shares of Holdings Common Stock prior to the closing of the Business Combination.

 

On October 28, 2025, Holdings entered into an advisory agreement with Legacy Cyabra and LifeSci Capital LLC (“LifeSci”) pursuant to which LifeSci will provide certain financial advisory and investment banking services to Cyabra. In connection with such engagement, LifeSci will receive a retainer fee of ordinary shares of Legacy Cyabra which will convert into 105,000 Holdings Shares upon the closing of the Business Combination and an advisory fee of $1,050,000 paid in Holdings Shares 90 days after the closing of the Business Combination. On June 29, 2026, the Company issued 262,500 shares of common stock to LifeSci.

 

F-8

 

 

On October 28, 2025, Holdings entered into an advisory agreement with Legacy Cyabra and Ladenburg pursuant to which Ladenburg will provide financial advisory and investment banking services to Cyabra. In connection with such engagement, Ladenburg will receive an advisory fee of $1,050,000 paid in Holdings Shares 90 days after the closing of the Business Combination. On June 29, 2026, the Company issued 262,500 shares of common stock to Ladenburg.

 

Attorney Shares

 

In connection with the Business Combination, on December 18, 2025, Trailblazer, Holdings and Legacy Cyabra entered into a subscription agreement with Loeb & Loeb LLP (“Loeb”), pursuant to which Legacy Cyabra agreed to issue to Loeb, immediately prior to the Closing, a convertible promissory note (the “Loeb Note”) in payment for certain legal fees and expenses due and owing by Trailblazer to Loeb through the closing of the Business Combination. The Loeb Note was initially convertible into securities of Legacy Cyabra and, upon the Closing, was assumed by Holdings and automatically converted into 1,000,000 shares of common stock of the Company (the “Loeb Shares”).

 

From and after the closing of the Business Combination, Loeb shall have the right to sell or otherwise dispose of the Loeb Shares in its sole discretion, at market prices, at prices related to such market prices, or at negotiated prices. Any net proceeds actually received from the sale of Loeb Shares shall be deemed to be payment, on a dollar for dollar basis, of fees owed to Loeb. To the extent that the total fee obligation is not fully paid from such net proceeds, Holdings and Legacy Cyabra shall be jointly and severally liable, pursuant to the terms of the note issuance agreement.

 

Upon payment in full of the total fee obligation and any premium, Loeb shall surrender to Holdings any unsold Loeb Shares. During the first and second quarters of 2026, Loeb sold all of the Loeb Shares. The proceeds from the sale, amounting to approximately $1,512 thousand, were offset against outstanding fees owed by the Company to Loeb.

 

On November 2, 2026, Loeb assigned to Alpha Capital Anstalt (“Alpha”) all of its rights and interests under the Note Issuance Agreement, including the outstanding payment obligations of the Company thereunder and any rights to receive promissory notes in respect thereof. Following the assignment, Alpha became the holder of such rights and obligations. The assignment did not, in itself, result in the settlement or extinguishment of the Company's outstanding obligations.

 

In connection with the Business Combination, on December 18, 2025, Trailblazer, Holdings and Legacy Cyabra entered into a subscription agreement with Lowenstein Sandler LLP (“Lowenstein”), pursuant to which Legacy Cyabra agreed to issue to Lowenstein, immediately prior to the Closing, a convertible promissory note (the “Lowenstein Note”) in payment for certain legal fees and expenses due and owing by Legacy Cyabra to Lowenstein through the closing of the Business Combination. The Lowenstein Note is expected to initially be convertible into securities of Legacy Cyabra and, upon the Closing, be assumed by Holdings and automatically convert into 1,000,000 shares of common stock of the Company (the “Lowenstein Shares”).

 

From and after the closing of the Business Combination, Lowenstein shall have the right to sell or otherwise dispose of the Lowenstein Shares in its sole discretion, at market prices, at prices related to such market prices, or at negotiated prices. Any net proceeds actually received from the sale of Lowenstein Shares shall be deemed to be payment, on a dollar for dollar basis, of fees owed to Lowenstein. To the extent that the total fee obligation is not fully paid from such net proceeds, Holdings and Legacy Cyabra shall be jointly and severally liable, pursuant to the terms of the note issuance agreement.

 

In consideration of Lowenstein’s agreement to enter into the note issuance agreement Lowenstein shall have the right to receive a premium if the total fee obligation is not paid in full by a certain date. Upon payment in full of the total fee obligation and any premium, Lowenstein shall surrender to Holdings any unsold Lowenstein Shares. During the second quarter of 2026, Lowenstein sold all of the Lowenstein Shares. The proceeds from the sale, amounting to approximately $590 thousand, were offset against outstanding fees owed by the Company to Lowenstein. During the three months ended September 30, 2026, the Company and Lowenstein agreed to settle the outstanding fee obligation, for a total amount of $1,000 thousand, of which $500 thousand was paid during the three months ended September 30, 2026, and the remaining $500 thousand was payable by October 31, 2026. As a result, the Company recognized a gain on settlement of accounts payable of approximately $631 thousand, presented within other income (expenses) in the condensed consolidated interim statements of operations for the three-and nine-month periods ended September 30, 2026. As of September 30, 2026, the remaining balance of $500 thousand was outstanding. On October 28, 2026, the Company paid the remaining balance in full.

 

F-9

 

 

Sponsor Promissory Note

 

On December 4, 2025, Parent entered into an amendment to the Second Amended and Restated Promissory note with the Parent’s sponsor (“Sponsor”), which still provides that in the event that Parent completes an initial Business Combination, all of the outstanding principal balance will convert into new classes of preferred stock of Parent or its successor with a total stated value of such preferred stock equal to 300% (100% Series B + 200% Series C) of the outstanding principal amount.

 

Upon the closing of the Business Combination, the Second Amended and Restated Promissory Note from Trailblazer to the Sponsor (as amended as of February 11, 2026) in the principal amount of $5.33 million was converted into preferred shares of Holdings with a stated value of $15.99 million. The outstanding principal balance converted into preferred stock with a total stated value of such preferred stock equal to 300% of the outstanding principal amount as follows: (a) the first 100% of the outstanding principal balance converted into shares of Holdings Series B Preferred Stock with an aggregate stated value equal to 100% of the outstanding principal amount, and (b) the remaining 200% of the outstanding principal balance converted into Holdings Series C Preferred Stock with a total stated value equal to 200% of the outstanding principal amount. The Preferred Shares (as defined below) were classified as permanent equity. On September 9, 2026, all outstanding Series B Preferred Stock was converted into common stock and pre-funded warrants, and all outstanding Series C Preferred Stock was exchanged for pre-funded warrants and Series A Common Warrants and Series B Common Warrants, as described in Note 4A.

 

PIPE Financing

 

Concurrently with the closing of the Business Combination, Holdings raised $8,000 thousand via a private placement (the “PIPE Financing”), in which the investors received Holdings Series B Preferred Stock and warrants, see also Note 3. On September 9, 2026, such Series B Preferred Stock were converted into common stock and pre-funded warrants, see Note 4A.

 

D. Going Concern: The Company has a limited operating history and faces a number of risks, among them: uncertainties regarding demand and market acceptance of the Company’s products, the effects of technological changes, competition and the development of new products. Additionally, other risk factors exist such as the ability to manage growth, the loss of key personnel and the effect of planned expansion of operations on the future results of the Company.

 

As from the date it commenced operations, the Company has devoted substantially all of its financial resources to develop its products and has financed its operations primarily through the issuance of equity securities and loans. The Company had accumulated losses in the amount of $64,174 thousand as of September 30, 2026. Cash flow used in operating activities was $9,567 thousand for the nine-month period ended September 30, 2026. In addition, the Company anticipates that it will continue to incur significant operating costs and losses in connection with the development of its products and with increased business development efforts. The amount of the Company’s future net profits or losses will depend, in part, on the rate of its future expenditures, its ability to generate significant revenues from the sale of its products, and its ability to obtain funding through the issuance of securities, strategic collaborations or grants. Based on the projected cash flows and cash balance as of September 30, 2026, management is of the opinion that without further fund raising it will not have sufficient resources to enable it to continue its operating activities, including the development and marketing of its products for a period of 12 months from the date these condensed consolidated interim financial statements are issued. As a result, there is a substantial doubt about the Company’s ability to continue as a going concern. Management’s plans include continuing commercialization of the Company’s products and securing sufficient funding through the sale of additional equity securities. There can be no assurance, however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and securing sufficient funding, it may need to reduce activities, curtail or even cease operations. The consolidated financial statements do not include any adjustments relating to the carrying amounts and classification of assets, liabilities, and reported expenses that might be necessary should the Company be unable to continue as a going concern.

 

F-10

 

 

Note 2 — Significant Accounting Policies

 

A. Unaudited condensed consolidated financial statements

 

The accompanying unaudited condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with GAAP for interim financial information and in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The unaudited condensed consolidated interim financial statements are comprised of the financial statements of the Company. In management’s opinion, the accompanying unaudited condensed financial statements reflect all adjustments necessary for a fair statement of its financial position as of September 30, 2026, and its results of operations for the nine and three months periods ended September 30, 2026 and 2025, and cash flows for the nine months periods ended September 30, 2026 and 2025. Operating results for the nine-month ended September 30, 2026 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2026. Certain amounts have been reclassified to a separate line item.

 

These unaudited condensed consolidated interim financial statements should be read in conjunction with Legacy Cyabra’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2025.

 

The unaudited condensed consolidated balance sheet as of December 31, 2025 has been derived from the audited annual financial statements of Legacy Cyabra included in the definitive proxy statement/prospectus filed with the SEC on March 27, 2026, but does not include all of the information and footnotes required under GAAP for a complete set of financial statements.

 

Following the Closing, the financial information included in these unaudited condensed consolidated financial statements includes the balances and results of operations of Holdings, which has become the reporting entity, and consolidates the balances and activity of Legacy Cyabra. Prior to the Closing, all references to Cyabra are related to the balances and activity of Legacy Cyabra. All intercompany balances have been eliminated in consolidation.

 

B. Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

 

Information about assumptions made by the Company with respect to the future and other reasons for uncertainty with respect to estimates that have a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next financial year are included in the following notes:

 

  - Fair value measurement of financial instruments

 

The Company accounts for financial liabilities arising from warrants, simple agreements for future equity (“SAFEs”) and convertible notes at fair value through profit or loss. The fair values of these instruments are determined using appropriate valuation methodologies. For additional information regarding fair value measurement, see Note 3.

 

  - Share-based payment awards

 

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. For the assumptions used to measure the share-based payments awards — see note 4.

 

C. Fair value of financial Instruments

 

Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and establishes a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price. In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company’s own credit risk.

 

F-11

 

 

As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

 

  ● Level 1 —Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.

 

  ● Level 2 — Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

 

  ● Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The financial instruments of the Company consist mainly of cash and cash equivalents, short-term restricted deposit, accounts receivable, other current assets, trade accounts payable, other current liabilities and loans. Due to their short-term nature, the carrying amounts of certain of these financial instruments approximate their fair values.

 

D. Credit Risk

 

The Company’s cash and cash equivalents balance is denominated mainly in U.S. dollars and New Israeli Shekels.

 

The Company does not have a significant concentration of credit risk. The cash of the Company is deposited in Israeli and U.S. banking institutions. Management does not expect material credit losses associated with these financial instruments.

 

E. Emerging Growth Company Accounting Elections

 

The Company qualifies as an emerging growth company (“EGC”) as defined under the Jumpstart Our Business Startups Act (the “JOBS Act”). Using exemptions provided under the JOBS Act for EGCs, the Company has elected to defer compliance with new or revised ASUs until it is required to comply with such updates, which is generally consistent with the adoption dates of private companies.

 

Note 3 — Financial Instruments

 

The following table sets forth the Company’s financial assets and liabilities that are measured at fair value, on a recurring basis:

 

    As of September 30, 2026  
    Level 1     Level 2     Level 3     Total  
    USD     USD     USD     USD  
    thousands     thousands     thousands     thousands  
Financial liabilities                        
Warrant Liability (PIPE)   $           -     $           -     $        14     $         14  
Total   $ -     $ -     $ 14     $ 14  

 

    As of December 31, 2025  
    Level 1     Level 2     Level 3     Total  
    USD     USD     USD     USD  
    thousands     thousands     thousands     thousands  
Financial liabilities                        
2024 Convertible Notes   $          -     $             -     $ 12,869     $ 12,869  
Warrants Liability     -       -       370       370  
Total   $ -     $ -     $ 13,239     $ 13,239  

 

F-12

 

 

Warrants liability

 

In May 2022, Legacy Cyabra signed a warrant agreement with Bank Hapoalim (the “Bank”) in the amount of $180 thousand, see note 6.A to Legacy Cyabra’s audited financial statements for the year ended December 31, 2025.

 

Prior to the Merger, the warrant was precluded from equity classification and was classified as a liability measured at fair value with changes in value recognized in the consolidated statements of operations.

 

The warrant’s liability’s fair value was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy.

 

As of December 31, 2025, the warrants were valued using a probability weighted expected return method (“PWERM”) valuation approach of two liquidation scenarios as follow: (1) a distribution in case of an IPO scenario, including a merger with a SPAC, with 95% probability as of December 31, 2025, in which the share capital will convert to common stocks and will be distributed at a price per stock equal to the Company value on the date of the IPO, divided by the total number of stocks and (2) a distribution in case of a merger and acquisition scenario, with 5% probability as of December 31, 2025, in which the total consideration will be distributed in accordance with the Liquidation Preferences and SAFE terms of each class of the stocks. For the IPO scenario the valuation based on the management’s assumption for its equity value, and discounted the equity value by the Company WACC of 25%. For the M&A scenario, the valuation used the Monte Carlo simulation. The Monte Carlo simulation included the following inputs:

 

    December 31,  
    2025  
Expected term     3 years  
Expected volatility     53.56 %
Risk-free interest rate     3.63 %
Expected dividend yield     -  

 

Upon the consummation of the Merger on March 27, 2026, the Company re-evaluated the terms of the Hapoalim Warrants in the context of the public company capital structure and finalized legal interpretations. Management determined that the Warrants met the requirements for equity classification under ASC 815-40 “Derivatives and Hedging — Contracts in Entity’s Own Equity”, as it is indexed to the Company’s own stock and is capable of settlement in shares within the Company’s control.

 

As a result, on the date of the Merger, the Hapoalim Warrant was remeasured to its fair value of $390 thousand, and the liability was reclassified to additional paid-in capital (permanent equity). No further remeasurement of the Hapoalim Warrant was required as of September 30, 2026.

 

The change in the fair value of the warrant liabilities measured utilizing Level 3 inputs for the nine months ended September 30, 2026, is summarized below.

 

Warrant liability at December 31, 2025   $ 370  
Change in fair value of warrant liability     20  
Reclassification to equity     (390 )
Warrant liability at September 30, 2026   $ -  

 

Convertible notes

 

On July 22, 2024, Legacy Cyabra entered into the Merger Agreement, see note 1.C.

 

On July 22, 2024, as part of the Merger Agreement, Alpha Capital Anstalt, a Liechtenstein Anstalt, an affiliate of the Sponsor, provided Legacy Cyabra a loan in an aggregate amount of $3,400 thousand in the form of convertible promissory notes (collectively, the “2024 Convertible Notes”) provided that Legacy Cyabra will have the ability to raise an additional $2,600 thousand (for a total aggregate amount of $6,000 thousand).

 

During the period from June until December 2024, and as a part of the 2024 Convertible Notes described above, Legacy Cyabra entered into agreements with several investors for issuance of convertible notes, for a total consideration of approximately $6,000 thousand.

 

F-13

 

 

In February 2025, Legacy Cyabra issued to Alpha Capital Anstalt, an affiliate of the Sponsor, a promissory note with a principal amount of $1,000 thousand. In December 2025, and since the promissory note was not repaid by then, Alpha Capital Anstalt and Legacy Cyabra signed an amendment to the promissory note, agreeing that it will be exchanged for a convertible note that is identical to the 2024 Convertible Notes.

 

The Convertible Notes converted as part of the Business Combination into Series B Preferred Stock of Legacy Cyabra, which were then converted to Holdings Series A Preferred Stock.

 

As of December 31, 2025, the 2024 Convertible Notes were in the legal form of debt and thus within the scope of ASC 470. Legacy Cyabra elected the fair value option for the 2024 Convertible Notes. Thus, the 2024 Convertible Notes were measured at fair value with subsequent changes recognized in the consolidated statement of operations.

 

As of December 31, 2025, the 2024 Convertible Notes were valued using a PWERM valuation approach of two liquidation scenarios as follow: (1) a distribution in case of an IPO scenario, including a merger with a SPAC, with 95% probability as of December 31, 2025, in which the share capital will convert to common stocks and will be distributed at a price per stock equal to Legacy Cyabra’s value on the date of the IPO, divided by the total number of stocks and (2) a distribution in case of an M&A scenario, with 5% probability as of December 31, 2025, in which the total consideration will be distributed in accordance with the Liquidation Preferences and SAFE terms of each class of the stocks. For the IPO scenario, the valuation was based on the management’s assumption for its equity value, and discounted the equity value by the Company’s WACC of 25%. For the M&A scenario, the valuation used the Monte Carlo simulation. The Monte Carlo simulation included the following inputs:

 

    December 31,  
    2025  
Expected term     3 years  
Expected volatility     53.56 %
Risk-free interest rate     3.63 %
Expected dividend yield     -  

 

Upon the consummation of the Merger on March 27, 2026, the 2024 Convertible Notes were converted to equity. On the date of the Merger, the 2024 Convertible Notes were remeasured to their fair value of $12,676 thousand, and the liability was reclassified to additional paid-in capital (permanent equity). No further remeasurement of the 2024 Convertible Notes was required as of September 30, 2026.

 

The change in the fair value of the 2024 Convertible Notes liability measured utilizing Level 3 inputs for the nine months ended September 30, 2026, is summarized below.

 

2024 Convertible Notes liability at December 31, 2025   $ 12,869  
Change in fair value of convertible notes liability     (193 )
Reclassification to equity     (12,676 )
2024 Convertible Notes liability at September 30, 2026   $ -  

  

PIPE Warrants

 

In connection with the PIPE Investment, Holdings issued warrants to the PIPE investors (the “PIPE Warrants”). Each PIPE Warrant will entitle the holder to purchase shares of Holdings Common Stock upon the terms summarized below.

 

Each PIPE Warrant will entitle the holder to purchase shares of Holdings Common Stock at an exercise price of $11.50 per share, subject to adjustment (as described below). The PIPE Warrants will be exercisable at any time beginning on the initial exercise date and will expire at 5:00 p.m. (New York City time) on the one-year anniversary of the initial exercise date, unless earlier terminated in accordance with their terms.

 

The PIPE Warrants are precluded from equity classification and are classified as liabilities measured at fair value with changes in value recognized in the consolidated statement of operations.

 

The warrant’s liability’s fair value was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy.

 

F-14

 

 

The warrants were valued using a Monte Carlo simulation. The Monte Carlo simulation included the following inputs:

 

    September 30,  
    2026  
Expected term     until March 27, 2027  
Expected volatility     80.08 %
Share price   $ 0.21  

 

The change in the fair value of the PIPE Warrant liabilities measured utilizing Level 3 inputs for the nine months ended September 30, 2026, is summarized below.

 

PIPE Warrant liability at March 27, 2026   $ 1,229  
Change in fair value of PIPE Warrant liability     (1,087 )
PIPE Warrant liability at March 31, 2026     142  
Change in fair value of PIPE Warrant liability     (109 )
PIPE Warrant liability at June 30, 2026   $ 33  
Change in fair value of PIPE Warrant liability     (19 )
PIPE Warrant liability at September 30, 2026   $ 14  

 

Note 4 — Equity

 

A. Preferred Shares

 

The Company’s Series A Convertible Preferred Shares, Series B Convertible Preferred Shares and Series C Convertible Preferred Shares (collectively, the “Preferred Shares”) were issued as part of the Business Combination. Each Preferred Share had a par value of $0.0001 per share and a stated value of $1,000. Prior to their conversion and/or exchange on September 9, 2026 (see below), the Preferred Shares had the following principal terms:

 

Holders were entitled to dividends equal to those paid on common stock, on an “as-if-converted-to-common-stock” basis, and no additional dividends were paid beyond those tied to common stock.

 

Preferred stock generally had no voting rights.

 

In the event of liquidation, holders were entitled to receive the stated value ($1,000 per share) plus accrued dividends before any distribution to common stockholders.

 

If assets were insufficient, distributions were made ratably among preferred stockholders.

 

Holders could convert their preferred stock into common stock at any time, based on the stated value divided by the conversion price.

 

The conversion price was subject to adjustments based on corporate actions such as stock splits, dividends, or reclassifications.

 

Conversion was restricted to ensure holders did not own more than 9.99% of the Company’s outstanding common stock.

 

Holders were also entitled to participate in rights offerings and distributions on an as-converted basis, subject to the terms of the applicable certificates of designation.

 

In the event of mergers, asset sales, or other major corporate changes, holders were entitled to receive equivalent consideration as common stockholders.

 

In addition, had the Company, within 18 months following the closing date, issued any securities at an effective per-share price lower than the then-current conversion price of the Preferred Share, the conversion price would have been adjusted to that lower price, subject to a floor equal to the greater of (i) USD 0.10, or (ii) 20% of the closing bid price of the common stock on the date immediately preceding the Merger date.

 

F-15

 

 

The Preferred Shares were classified as equity with all embedded features closely related to the host equity contract, and were presented within permanent equity under ASC 480-10-S99-3A “Classification and Measurement of Redeemable Securities”, since upon a liquidation event, holders of equally and more subordinated equity instruments would also be entitled to receive the same form of consideration.

 

Upon the closing of the private placement in July 2026 (see Note 8.G), the down round feature of the Preferred Shares was triggered, and their conversion price was reduced to the floor price of $1.46 per share. The effect of a triggered down round feature is measured as the difference between the fair value of the Preferred Shares immediately before and immediately after the reduction of the conversion price, and is recognized as a deemed dividend in computing net loss attributable to common stockholders. Since the conversion feature of the Preferred Shares was significantly out-of-the-money both before and after the reduction, the difference was immaterial, and accordingly no deemed dividend was recognized in respect of the down round feature.

 

On July 9, 2026, in connection with the private placement described in Note 8.G, the Company entered into (i) an exchange agreement (the “Exchange Agreement”) with Alpha Capital Anstalt, the holder of all outstanding Series C Preferred Shares, and (ii) a conversion agreement (the “Conversion Agreement”) with the holders of the Series A Preferred Shares and Series B Preferred Shares. The transactions were subject to, among other conditions, stockholder approval, which was obtained at a special meeting of stockholders held on September 2, 2026. On September 3, 2026, the Company filed amendments to the Certificates of Designation of the Series A Preferred Shares and Series B Preferred Shares with the Secretary of State of the State of Delaware, reducing the conversion price of each such series to $0.435 per share.

 

Both transactions closed on September 9, 2026, as follows:

 

Series A Preferred Shares and Series B Preferred Shares – Pursuant to the Conversion Agreement, all outstanding Series A Preferred Shares and Series B Preferred Shares, consisting of 2,177 Series A Preferred Shares and 12,945 Series B Preferred Shares, were converted into 9,756,323 shares of common stock and a pre-funded warrant to purchase up to 25,006,895 shares of common stock, at an exercise price of $0.0001 per share.

 

Series C Preferred Shares – Pursuant to the Exchange Agreement, all 10,660 outstanding Series C Preferred Shares were exchanged for: (i) pre-funded warrants to purchase 24,505,747 shares of common stock at an exercise price of $0.0001 per share, exercisable immediately and until exercised in full; (ii) Series A warrants to purchase 24,505,747 shares of common stock at an exercise price of $0.50 per share, expiring five years from the initial exercise date; and (iii) Series B warrants to purchase 24,505,747 shares of common stock at an exercise price of $0.45 per share, expiring twelve months from the initial exercise date.

 

Upon closing, the converted and exchanged Preferred Shares were cancelled and restored to the status of authorized but unissued shares, and the conversion price adjustment provisions described above were eliminated. As of September 30, 2026, no Preferred Shares were outstanding.

 

The pre-funded warrants and the Series A Common Warrants and Series B Common Warrants are classified within stockholders’ equity, as they are indexed to the Company’s own stock and meet the conditions for equity classification under ASC 815-40.

 

The Company accounted for the conversion of the Series A Preferred Shares and Series B Preferred Shares (including the reduction of their conversion price from $1.46 to $0.435 per share) and the exchange of the Series C Preferred Shares as extinguishments. Accordingly, the Company derecognized the carrying amount of the Preferred Shares and recognized the common stock, pre-funded warrants and Series A Common Warrants and Series B Common Warrants issued at their fair value. The excess of the fair value of the consideration issued over the carrying amount of the Preferred Shares was recognized as a deemed dividend. The deemed dividend had no effect on total stockholders’ equity and was deducted in determining net loss attributable to common stockholders for purposes of computing basic and diluted loss per share (see Note 5).

 

B. Share-Based Compensation

 

The stock-based compensation expense recognized in the financial statements for services received is related to research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses as shown in the following table:

 

    Nine months ended
September 30,
    Three months ended
September  30,
 
    2026     2025     2026     2025  
    USD
thousands
    USD
thousands
    USD
thousands
    USD
thousands
 
Stock-based compensation expense – R&D   $ 3,055     $ 991     $ 224     $ 125  
Stock-based compensation expense – S&M     274       508       185       103  
Stock-based compensation expense – G&A     1,808       1,204       297       220  
Total   $ 5,137     $ 2,703     $ 706     $ 448  

 

F-16

 

 

In June 2020, Legacy Cyabra adopted the 2020 Share Option Plan for Legacy Cyabra’s officers, directors, employees, consultants and other service providers.

 

On February 10, 2026, Legacy Cyabra granted a total of 65,797 options to its employees.

 

Upon the closing of the Business Combination on March 27, 2026, and pursuant to the Merger Agreement, the Key Employees received a total of 400,000 RSUs is settleable into shares of Holdings Common Stock pursuant to the 2026 Plan. The RSUs were fully vested as of the closing of the Business Combination. Accordingly, the Company recognized the full compensation expense based on the fair value of the RSUs at the grant date, with a corresponding credit to additional paid-in capital.

 

On May 14, 2026, the Company granted 1,615,536 RSUs to its employees, advisors and board members. The total fair value of this grant was $968 thousand.

 

On August 13, 2026, the Company granted 103,000 RSUs to its employees. The total fair value of this grant was $40 thousand.

 

In addition to the above, the Company recognized stock-based compensation expense of $1,009 thousand in connection to the shares granted to LifeSci, see note 1.C.

 

During the nine-month period ended September 30, 2026, 322,069 options were exercised, 131,088 options were forfeited and 91,571 options expired.

 

The fair value of each option award granted in February 2026 is estimated on the date of grant using the Black-Scholes option-pricing model that used the weighted average assumptions in the following table:

 

    2026
Grants
 
Dividend yield   $ -  
Expected volatility     60.78 – 61.84 %
Risk-free interest     3.77-3.82 %
Expected term     5.64 – 6.13 years  
Exercise price   $ 0.16 – 9.37  
Share price   $ 11  
Total fair value (USD Thousands)   $ 626  

 

Note 5 — Loss per Share

 

The Company computes net loss per share using the two-class method required for participating securities. The two-class method requires income available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Until their conversion and exchange on September 9, 2026, the Company considered its Preferred Shares and its redeemable convertible preferred shares to be participating securities, as the holders were entitled to dividends distributed to the holders of common stock on an as-if converted basis. These participating securities did not contractually require the holders of such shares to participate in the Company’s losses. As such, net loss for the periods presented was not allocated to the Company’s participating securities.

 

The Company’s basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common stock outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive shares of common stock are anti-dilutive.

 

F-17

 

 

Pre-funded warrants, which are exercisable for nominal consideration of $0.0001 per share, are considered outstanding shares of common stock for purposes of computing basic and diluted net loss per share from the date of their issuance, to the extent that the shares issuable upon their exercise are issuable for immaterial consideration and no substantive conditions to issuance remain outstanding.

 

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:

 

    Nine months
ended
September 30,
    Three months
ended
September 30,
 
    2026     2026  
Basic and diluted net loss per share:            
Net loss for the period     (16,801 )     (2,592 )
Deemed dividend on extinguishment of Preferred Shares     (2,569 )     (2,569 )
Net loss attributable to common stockholders     (19,370 )     (5,161 )
Weighted average number of common stock, basic and diluted     19,413,724       41,077,186  
Net loss per share attributable to common stockholders, basic and diluted   $ (1.00 )   $ (0.13 )

 

    Nine months
ended
September 30,
    Three months
ended
September 30,
 
    2025     2025  
Basic and diluted net loss per share:            
Net loss for the period     (8,501 )     (2,741 )
Deduct redeemable convertible preferred shares cumulative dividend     (500 )     (188 )
Net loss attributable to common stockholders     (9,001 )     (2,929 )
Weighted average number of common stock, basic and diluted     2,511,059       2,737,168  
Net loss per share attributable to common stockholders, basic and diluted   $ (3.58 )   $ (1.07 )

 

In computing diluted loss per share for the three and nine months ended September 30, 2026 and 2025, no account was taken of the potential dilution that could occur upon the exercise of outstanding warrants and stock options, the vesting or settlement of RSUs, and the issuance of other contingently issuable shares, as applicable, including the effects of convertible notes and convertible preferred shares during periods in which such instruments were outstanding, amounting to 79,847 thousand and 7,105 thousand shares potentially issuable as of September 30, 2026 and 2025, respectively, since they had an anti-dilutive effect on net loss per share.

 

Note 6 — Segment Information

 

The Company operates as a single operating segment and addresses the threat of coordinated online manipulation and inauthentic activity for brands and the public sector and provide software that identifies bad actors online and mitigates the threat in real-time. The Company’s CODM is its Chief Executive Officer (CEO). The CODM reviews the Company’s performance on a consolidated basis. The CODM evaluates the Company’s performance and allocates resources by reviewing financial metrics like budget versus actual results and expenditures, as well as cash balances. This enables strategic adjustments to support operational and financial goals. As such, the segment’s loss is the Company’s consolidated net loss and the segment’s assets are the Company’s consolidated cash and cash equivalents.

 

F-18

 

 

Segment disclosures

 

The CODM reviews the Company’s results on a consolidated basis. As such, information on segment loss and significant expenses is similar to the Company’s consolidated statements of operations. The CODM is also regularly provided with information on significant expenses and cash and cash equivalents balances, as follows:

 

    Nine months ended
September 30,
    Three months ended
September 30,
 
    2026     2025     2026     2025  
    USD thousands     USD thousands     USD thousands     USD thousands  
Revenues   $ 5,271     $ 4,078     $ 2,003     $ 1,487  
Less:                                
Cost of revenues     800       584       304       175  
R&D expenses- excluding stock-based compensation expenses     6,687       4,356       1,950       1,532  
S&M expenses- excluding stock-based compensation expenses     3,717       3,935       1,247       1,147  
G&A expenses- excluding stock-based compensation expenses     6,082       2,115       1,013       343  
Stock based compensation expenses     6,146       2,703       706       448  
Operating loss     18,161       9,615       3,217       2,158  
Finance expenses (income)     (794 )     (1,134 )     5       582  
Other expenses (income)     (631 )     -       (631 )     -  
Taxes on income     65       20       1       1  
Net loss     16,801       8,501       2,592       2,741  
Cash and cash equivalents (Bank overdraft)   $ 1,342     $ (43 )   $ 1,342     $ (43 )

 

Note 7 — Revenues

 

Contract Assets and Liabilities

 

The following table provides information about accounts receivable and contract liabilities from contracts with customers:

 

    September 30,
2026
    December 31,
2025
 
    USD thousands  
Accounts receivable   $ 433     $ 269  
Contract liabilities (deferred revenues) – short term   $ 2,779     $ 2,816  
Contract liabilities (deferred revenues) – long term   $ 586     $ 115  

 

Remaining Performance Obligations

 

Remaining performance obligations represent contracted revenue that had not yet been recognized, and include billed deferred revenue, consisting of amounts invoiced to customers whether collected or uncollected, that have not been recognized as revenue, as well as unbilled amounts that will be invoiced and recognized as revenue in future periods. As of September 30, 2026, the Company’s remaining performance obligations were $3,977 thousand, of which the Company expects to recognize $3,391 thousand and $586 thousand as revenue within the next twelve months and thereafter, respectively.

 

F-19

 

 

Note 8 — Significant Events During the Reporting Period

 

A. On January 8, 2026, Legacy Cyabra received a $200 thousand promissory note from Alpha Capital Anstalt, bearing annual interest of 10%. The principal will be repaid with 50% of all gross revenues or proceeds from any financing, net of any reseller or broker fee, and the remaining unpaid principal will be repaid upon the earlier of the closing of the business combination with Trailblazer Merger Corporation I or January 22, 2026. The accrued interest will be repaid in cash in accordance with the terms of the note. The note was repaid at the closing of the business combination.

 

B. On February 5, 2026, Legacy Cyabra received a loan evidenced by a promissory note in the principal amount of $1,000 thousand from Alpha Capital Anstalt, bearing annual interest of 10%. The principal was required to be repaid with 50% of all gross revenues or proceeds from any financing, net of any reseller or broker fee, and the remaining unpaid principal was due upon the earlier of the closing of the business combination with Trailblazer Merger Corporation I or February 18, 2026. The accrued interest was payable in cash in accordance with the terms of the note. As of the date of these financial statements, this note was due but remained outstanding. As a result of the note not being repaid when due, the interest rate was adjusted in accordance with the contractual terms of the note.

 

C. On January 14, 2026, Legacy Cyabra received a bridge loan from the Bank in the amount of $524 thousand. The loan bore interest at 10.50% per annum and was repaid on January 31, 2026.

 

D. On March 2, 2026, Legacy Cyabra received a bridge loan from the Bank in the amount of $131 thousand. The loan bore interest at 10.50% per annum and was scheduled to mature on March 16, 2026. The loan was repaid and received again, bearing an interest of 11% per annum, and was repaid on March 26, 2026.

 

E. On March 9, 2026, Legacy Cyabra received $450 thousand promissory note from Alpha Capital Anstalt, bearing annual interest of 10%. The principal will be repaid with 50% of all gross revenues or proceeds from any financing, net of any reseller or broker fee, and the remaining unpaid principal will be repaid upon the earlier of the closing of the business combination with Trailblazer Merger Corporation I or March 19, 2026. The accrued interest will be repaid in cash in accordance with the terms of the note. As of the date of these financial statements, this note was due but was not yet repaid. As a result of the note not being repaid when due, the interest rate was adjusted in accordance with the contractual terms of the note.

 

F. On March 13, 2026, Legacy Cyabra received a loan evidenced by a promissory note in the principal amount of $350 thousand from Alpha Capital Anstalt, bearing annual interest of 10%. The principal was required to be repaid with 50% of all gross revenues or proceeds from any financing, net of any reseller or broker fee, and the remaining unpaid principal was due upon the earlier of the closing of the business combination with Trailblazer Merger Corporation I or March 27, 2026. The accrued interest was payable in cash in accordance with the terms of the note. The note was repaid at the closing of the business combination.

 

G. On July 9, 2026, the Company entered into securities purchase agreements (each, a “Purchase Agreement”) for the issuance of an aggregate of 1,175,090 shares (the “Shares”) of common stock, par value $0.0001 per share, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 12,643,680 shares of common stock (the “Pre-Funded Warrant Shares”), at a purchase price of $0.435 per Share and $0.4349 per Pre-Funded Warrant, Series A warrants (the “Series A Common Warrants”) to purchase up to 13,818,770 shares of common stock (the “Series A Common Warrant Shares”), at an exercise price of $0.50 and Series B warrants (the “Series B Common Warrants”) to purchase up to 13,818,770 shares of common stock (the “Series B Common Warrant Shares”), at an exercise price of $0.45. The offering (the “Offering”) closed on July 10, 2026. Out of the Shares, 275,890 were issued to directors and officers that participated in the Offering under the same terms as other investors for total proceeds of approximately $120 thousand. The gross proceeds from the Offering, before deducting placement agent fees and other offering expenses, were approximately $6 million. The net proceeds after deducting placement agent fees and other offering expenses were approximately $5.3 million. The Pre-Funded Warrants are exercisable immediately upon issuance and remain exercisable until exercised in full. The Series A Common Warrants became exercisable on September 2, 2026, the date stockholder approval was obtained, and will expire five years from that date. The Series B Common Warrants  became exercisable on September 2, 2026 and will expire twelve months from that date.

 

 

On July 9, 2026, the Company entered into an exchange agreement (the “Exchange Agreement”) with Alpha Capital Anstalt (the “Holder”) that holds the outstanding Series C Convertible Preferred Stock, pursuant to which the Holder agreed to exchange at the Exchange Closing (as defined in the Exchange Agreement) an amount of Series C Preferred Shares with an aggregate value of $10,660,000 (the “Preferred Shares Value”), and the Company agreed to issue to the Holder, in the exchange therefor: (i) the number of shares of common stock; (ii) if applicable, the Pre-Funded Warrants; and (iii) the Series A Common Warrants and the Series B Common Warrants as if the Holder had invested additional cash equal to the Preferred Shares Value in the Offering mentioned in section G above. Effective upon the Exchange Closing, the Exchange Preferred Shares (as defined in the Exchange Agreement) shall automatically be cancelled, retired and restored to the status of authorized but unissued shares of the Series C Preferred Shares. The Exchange Closing was subject to stockholder approval, which was obtained on September 2, 2026.

 

On July 9, 2026, the Company entered into a conversion agreement (the “Conversion Agreement”) with the holders (the “Holders”) of an aggregate of 15,507 shares of Series A Preferred Shares and Series B Convertible Preferred Stock (“Series B Preferred Shares” and together with the Series A Preferred Shares, the “Preferred Shares”), convertible into an aggregate of 35,648,276 shares of common stock at the reduced conversion price described below, pursuant to which the Holders agreed that upon the Conversion Closing (as defined in the Conversion Agreement), all of the outstanding Preferred Shares (the “Committed Preferred Shares”) shall be deemed to have been converted (the “Conversion”) into shares of common stock (or pre-funded warrants in lieu thereof). Pursuant to the Conversion Agreement, the Company and the Holders agreed to amend the terms of the Certificates of Designation governing the Preferred Shares to reduce the conversion price of each class of Preferred Shares to $0.435 per share. The Conversion was subject to stockholder approval, which was obtained on September 2, 2026.

 

F-20

 

 

H. On September 2, 2026, the Company’s stockholders approved the conversion of all outstanding Series A Preferred Shares and Series B Preferred Shares and the exchange of all outstanding Series C Preferred Shares, pursuant to agreements entered on July 9, 2026. The transactions closed on September 9, 2026, at which time all outstanding Series A, Series B and Series C Preferred Shares were converted into, or exchanged for, shares of common stock, pre-funded warrants and common stock warrants, and the conversion price adjustment provisions of the preferred shares were eliminated. As of September 30, 2026, no preferred shares were outstanding. See Note 4A.

 

Note 9 — Subsequent Events

 

A. On November 9, 2026, the Company entered into a Secured Promissory Note and Security Agreement (the “Note and Security Agreement”) with Alpha Capital Anstalt (the “Lender”), pursuant to which the Lender agreed to provide the Company with financing in an aggregate principal amount of up to $1,500,000, to be funded in tranches agreed to between the Company and the Lender. On November 9, 2026, the Lender funded an initial tranche in the principal amount of $650,000. Amounts outstanding under the Note and Security Agreement accrue interest at a rate of 10% per annum. Following the occurrence and during the continuance of an Event of Default (as defined in the Note and Security Agreement), the interest rate increases to the lesser of 18% per annum or the highest rate permitted by applicable law. The outstanding principal amount, together with accrued interest, is due on January 15, 2027, provided that the Lender has the right to extend the maturity date in three-month increments until December 31, 2028.
   
B. On November 4, 2026, the Company’s Board of Directors approved a 1-for-30 reverse stock split of the Company’s common stock, subject to stockholder approval. On November 10, 2026, the Company’s stockholders authorized the Company’s Board of Directors to effect a reverse stock split (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective later in November 2026. All references made to share or per share amounts in the accompanying unaudited condensed consolidated interim financial statements and applicable disclosures herein, unless otherwise indicated, are presented on a pre-reverse split basis.

 

The following table provides pro forma loss per share of common stock, giving retroactive effect to the Reverse Stock Split:

 

    Nine months ended
September 30,
    Three months ended
September 30,
 
    2026     2025     2026     2025  
Numerator:                        
Net loss for the period     (16,801 )     (8,501 )     (2,592 )     (2,741 )
Net loss attributable to common stockholders, basic and diluted     (19,370 )     (9,001 )     (5,161 )     (2,929 )
Denominator:                                
Weighted-average number of common stock used in computing net loss per share attributable to common stockholders, basic and diluted - pro forma     647,124       83,702       1,369,240       91,239  
Net loss per share attributable to common stockholders, basic and diluted – pro forma     (29.93 )     (107.53 )     (3.77 )     (32.10 )

 

The number of issued and outstanding shares of common stock, giving retroactive effect to the Reverse Stock Split, as of September 30, 2026, and December 31, 2025, is 1,109,487 and 100,652, respectively.

 

C. On November 12, 2026, the Company granted 17,700,000 RSUs to its executives, directors, advisors and employees.
   
D.

On November 15, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Alpha Capital Anstalt and certain other purchasers, pursuant to which the Company agreed to issue and sell shares of newly designated Series D Convertible Preferred Stock (the “Series D Preferred Stock”) and warrants to purchase shares of the Company's common stock (the “Warrants”) in a private placement offering for aggregate consideration of up to approximately $45.6 million.

 

The Purchase Agreement contemplates an initial closing with an aggregate subscription amount of approximately $15.6 million, consisting of $10 million in new investment and approximately $5.6 million in subscription consideration to be satisfied through the cancellation of approximately $2.8 million of outstanding indebtedness of the Company. The Series D Preferred Stock will have a stated value of $1,000 per share and will be convertible into common stock at an initial conversion price of $0.15 per share, subject to adjustment. The Warrants will have an initial exercise price of $0.15 per share, subject to adjustment, and will become exercisable following receipt of the required stockholder approval.

 

The Purchase Agreement also provides for potential additional investments of up to $30 million over a three-year period, subject to the terms and conditions set forth therein.

 

The initial closing is subject to certain conditions, including receipt of the required stockholder approvals and confirmation from Nasdaq that the Company has cured its listing deficiencies and that its continued listing has been approved. As of the date of issuance of these condensed consolidated interim financial statements, the initial closing has not occurred. There can be no assurance that the initial closing or any subsequent investments will be consummated.

 

F-21

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

  

On March 27, 2026 (the “Effective Time” or “Closing”), Cyabra Strategy Ltd. (“Legacy Cyabra”) and Trailblazer Holdings, Inc. (“Holdings”) consummated the business combination (the “Business Combination”) as contemplated by a definitive business combination agreement and Holdings changed its name to Cyabra, Inc. (the “Company” or “Cyabra”). As a result, the financial statements of Legacy Cyabra are now the financial statements of the Company. The following discussion and analysis of the financial condition and results of operations should be read together with our condensed consolidated financial statements for the nine and three months ended September 30, 2026 and 2025, and the related notes included elsewhere in this Quarterly Report on Form 10-Q and Legacy Cyabra’s audited financial statements for the year ended December 31, 2025 and the related notes incorporated by reference into the Company’s Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2026.

 

2

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “can,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential” and other similar words and expressions of the future.

 

There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:

 

  ● expectations regarding our strategies and future financial performance, including our future business plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures, and our ability to invest in growth initiatives and pursue acquisition opportunities;

 

  ● the outcome of any legal proceedings that may be instituted against us following the Closing;

 

  ● our ability to successfully integrate and operate as a public company following the Business Combination, including our ability to maintain effective internal controls, comply with reporting obligations, and manage increased legal, regulatory, and compliance costs;
     
  ● our expectations regarding future revenue growth, contract renewals, customer demand, and the conversion of bookings and annualized recurring revenue into recognized revenue, which are subject to the timing of customer purchasing decisions, contract terms, and revenue recognition requirements;
     
  ● our ability to recognize the anticipated benefits of the Business Combination;

 

  ● our ability to retain key executives;

 

  ● limited liquidity and trading of our securities;

 

  ● geopolitical risk and changes in applicable laws or regulations;

  

  ● the size of the addressable markets for our products and services;

 

  ● the possibility that we may be adversely affected by other economic, business, and/or competitive factors;

 

  ● our ability to regain compliance with Nasdaq’s continued listing requirements and maintain the listing of our common stock on The Nasdaq Stock Market LLC (“Nasdaq”);

 

  ● our ability to obtain additional financing on acceptable terms, including the completion of any pending financing transactions, and our ability to continue as a going concern; and

 

  ● operational risk.

 

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in such forward-looking statements. Please see “Part II-Item 1A-Risk Factors” for additional risks which could adversely impact our business and financial performance.

 

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished.

 

3

 

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS OF CYABRA

 

The following discussion and analysis of Cyabra’s financial condition and results of operations should be read in conjunction with Cyabra’s consolidated financial statements and the notes related thereto which are included elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those set forth under “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and elsewhere in this Quarterly Report.

 

Overview

 

Cyabra is an entity that was formed for the purpose of effecting the Business Combination and now serves as a publicly-traded company. Its wholly owned subsidiary is Legacy Cyabra, an Israeli company that was formed on July 13, 2017. Cyabra uncovers disinformation spread online. Disinformation diminishes trust, creates false or negative narratives and content and sows dissension. Creators of disinformation may be sponsored by foreign governments, competitors, or other third parties with significant resources and access to highly sophisticated generative artificial intelligence tools that generate and spread fake content. They use these tools to create both networks and fake social media accounts to disseminate disinformation, inciting fear, anger and distrust and making us question everything we see or read. These tools make it difficult for the targets of the disinformation, whether they are corporations or public sector agencies, to detect and combat its spread. In many cases, these targets do not have the tools or expertise to effectively identify or counteract the threat. As fake accounts using enhanced AI tools appear more and more authentic, the line between real and fake is disappearing. Cyabra combats disinformation by leveraging advanced artificial intelligence (“AI”) and machine learning technologies to monitor and analyze online conversations in real-time. Developed by experts in information warfare, Cyabra’s platform collects publicly available data from social media and news sites. The platform applies Cyabra’s proprietary algorithms to assess authenticity and sentiment, enabling Cyabra to identify fake accounts, uncover harmful narratives, detect GenAI text and images, and filter between real and fake profiles, helping customers protect their brand reputation and ensure the authenticity of online discourse about them.

 

Cyabra analyzes patterns typical of fake profiles spreading harmful narratives, tracking the source and spread of information to measure its reach and impact. This comprehensive approach enables customers to understand narratives, discover trends, and identify attempts to influence public opinion, safeguarding public trust and maintaining the integrity of online spaces against long-established disinformation threats as well as newer AI-driven harms.

 

Components of Operating Results

 

Revenue

 

Cyabra offers its technology solution primarily on a software-as-a-service (SaaS) subscription basis under which customers purchase a subscription to access Cyabra’s suite of tools through a website hosted by a third-party service provider. Subscriptions are non-refundable and generally have terms ranging from several months to three years. These customers receive access to the website through a secure connection. Certain customers, particularly governmental agencies, may want or need to host Cyabra’s application on their own server network. Where appropriate, Cyabra will sell licenses to such customers, which have a term of two to three years, under which the customers have the ability to install the application locally. Other potential customers may want to access Cyabra’s tools for a limited purpose or for a limited period of time, such as for tracking the reaction of customers to a promotion or a change in the user’s business practices. Other potential users wish to sample the utility of Cyabra’s solution before committing to a long-term subscription. For these customers, Cyabra provides managed services, under which a customer pays fees for a report or a package of several reports prepared by Cyabra directly based on agreed-upon criteria using its own in-house resources. Cyabra recognizes revenue from its SaaS and on-premises services ratably over the period in which the services are rendered. Cyabra’s customers usually pay for the services in advance for the duration of the subscription or license which are recorded as deferred revenue and recognized ratably over the term of the subscription or license. Revenues relating to managed services are recognized at the point in time at which the deliverable is transferred to the customer.

 

4

 

 

Legacy Cyabra began offering its application to customers in 2022 and to date has generated limited revenues. Consequently, Cyabra has funded its operations principally through the issuance of equity securities, convertible securities and borrowings. Cyabra’s ability to generate significant revenues and achieve profitability depends on its ability to successfully continue to develop and commercialize its application and solutions provided by its applications. As of September 30, 2026, Cyabra had an accumulated deficit of approximately $64.2 million. Cyabra expects to incur significant expenses and operating losses in the future as it grows its business and continues to develop and commercialize its application and solutions provided by its applications. Furthermore, Cyabra expects to incur additional costs associated with operating as a public company. Cyabra will need to generate significant revenues to achieve profitability and may never do so. See “Liquidity and Capital Resources” below for a discussion of our liquidity requirements, financing activities and substantial doubt about our ability to continue as a going concern.

 

Cost of Revenues

 

Cost of revenues consists primarily of costs of servers and services, salaries and related personnel expenses and royalties paid to the Israel Innovation Authority. Cyabra expects its cost of revenues to increase as its business grows and it continues to develop and commercialize its application and solutions provided by its applications.

 

Operating Expenses

 

Cyabra’s current operating expenses consist of research and development expenses, sales and marketing expenses, and general and administrative expenses.

 

Research and Development Expenses

 

Cyabra’s research and development expenses consist of salaries and related personnel expenses, share-based compensation expenses, software and storage expenses, rental fees, consultants, and other related research and development expenses. Cyabra expenses research and development costs as incurred.

 

Sales and Marketing Expenses

 

Sales and marketing expenses consist primarily of salaries and related personnel expenses, as well as share-based compensation expenses, reseller fees and commissions, subcontractors, conferences and exhibitions costs, travel expenses and other sales and marketing costs. Cyabra expects that sales and marketing expenses will increase in the future as Cyabra increases its commercialization efforts.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of professional services, share-based payments expenses, salaries and related expenses, insurance expenses, travel expenses, and other general and administrative expenses. Cyabra expects that general and administrative expenses will increase in the future as Cyabra increases its general and administrative headcount to support the commercialization of its products. Cyabra also expects to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax compliance services, directors’ and officers’ insurance, and investor and public relations costs.

 

Finance Expense and Income

 

Finance expense and income mainly consist of revaluation of financial liabilities, interest expenses, exchange rate differences and bank fees.

 

5

 

 

Select Performance Metrics and Non-GAAP Financial Measures

 

Cyabra uses annualized recurring revenues (“ARR”) as a performance metric in managing its business. Cyabra defines ARR as of a specific date as the annualized recurring revenue of signed term-based contracts, including contracts for which services have not yet commenced, from all customers with a term of at least 12 months. ARR is calculated by dividing the total contract value of each signed contract with a term of at least 12 months by the number of years in the term. ARR represents the annualized contract value for all contractually binding term-based contracts at the end of a period. Management uses ARR to understand customer trends and the overall health of Cyabra’s business, helping it to formulate strategic business decisions.

 

ARR is not defined in accounting principles generally accepted in the United States (“GAAP”) and is not derived from GAAP measure. ARR should be viewed independently of revenue and deferred revenue and is not intended to be combined with or to replace either of those items. ARR is not a forecast and the active contracts at the end of a reporting period used in calculating ARR may or may not be extended or renewed by our customers. ARR does not represent revenue recognized during a particular period or cash expected to be received during any particular period, and actual revenue recognized under the contracts included in ARR may differ from the amounts reflected in ARR as a result of contract terms, the timing of performance obligations and other factors.

 

The metrics Cyabra uses to evaluate its business are periodically reviewed and revised to reflect changes in its business. Because Cyabra commenced offering its application in 2022, is still developing and implementing its commercial business strategy and is at an early stage of its commercial operations, it does not believe that metrics related to customer retention or renewals are reliable metrics on which to measure its performance and management does not use such metrics to manage Cyabra’s business. Such metrics may become relevant once Cyabra has a longer history of performance.

 

In addition, we believe that non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as management. As these measures are not financial measures calculated in accordance with GAAP, they should not be considered as substitutes for financial measures that have been calculated in accordance with GAAP. We primarily review the following non-GAAP measures when assessing our performance:

 

Adjusted EBITDA

 

In addition to our financial results determined in accordance with GAAP, we believe that adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”), as a non-GAAP measure, is useful in evaluating our operating performance. We define Adjusted EBITDA as net loss before depreciation and amortization, income taxes, net finance expenses and income, stock-based compensation expenses, non-recurring expenses related to the Business Combination and certain other non-operating gains. We use Adjusted EBITDA to evaluate our ongoing operations. We believe that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In particular, Adjusted EBITDA excludes stock-based compensation expense, which has been, and is expected to continue to be, a significant recurring expense and an important component of our compensation arrangements. Adjusted EBITDA also does not reflect our cash requirements for capital expenditures or working capital needs. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measure as a tool for comparison. A reconciliation is provided below for our non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measure and the reconciliation of this non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate our business.

 

6

 

 

Adjusted EBITDA

 

    Nine Months Ended
September 30,
    Three Months Ended
September 30,
 
    2026     2025     2026     2025  
    USD
Thousands
    USD
Thousands
    USD
Thousands
    USD
Thousands
 
Net loss     (16,801 )     (8,501 )     (2,592 )     (2,741 )
Depreciation and amortization     46       42       17       13  
Income taxes     65       20       1       1  
Finance expenses (income), net     (794 )     (1,134 )     5       582  
EBITDA     (17,484 )     (9,573 )     (2,569 )     (2,145 )
Stock based compensation expenses (1)     6,146       2,703       706       448  
Non-recurring expenses related to the Business Combination (2)     3,438       -       -       -  
Other non-operating gain (3)     (631 )     -       (631 )     -  
Adjusted EBITDA     (8,531 )     (6,870 )     (2,494 )     (1,697 )

 

(1) Represents non-cash charges associated with stock-based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of our compensation strategy.

 

(2) Represents non-recurring costs related to our Business Combination, including bonus expenses to several employees in connection with the Business Combination.
   
(3) Represents non-operating gain on settlement of accounts payable.

 

Critical Accounting Policies

 

Cyabra’s consolidated financial statements are prepared in accordance with GAAP and have been prepared on a going concern basis. However, as described under “Liquidity and Capital Resources,” substantial doubt exists about our ability to continue as a going concern.

 

Our significant accounting policies are described in the notes to our condensed consolidated financial statements and in our audited consolidated financial statements for the year ended December 31, 2025. There have been no material changes to our critical accounting estimates during the nine months ended September 30, 2026, except as otherwise disclosed in the accompanying financial statements.

 

The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

 

Information about assumptions made by Cyabra with respect to the future and other reasons for uncertainty with respect to estimates that have a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next financial year are included in Cyabra’s financial statements and accompanying notes.

 

7

 

 

Results of Operations

 

Comparison of the nine months ended September 30, 2026 to the nine months ended September 30, 2025

 

The following table summarizes Cyabra’s results of operations for the nine months ended September 30, 2026 and 2025:

 

    Nine Months Ended
September 30,
 
    2026     2025  
    USD
Thousands
    USD
Thousands
 
Revenues     5,271       4,078  
Cost of revenues     800       584  
Gross profit     4,471       3,494  
Operating costs and expenses                
Research and development expenses     9,742       5,347  
Sales and marketing expenses     3,991       4,443  
General and administrative expenses     8,899       3,319  
Total operating loss     18,161       9,615  
Financing income, net     (794 )     (1,134 )
Other Income     (631 )     -  
Loss before taxes on income     16,736       8,481  
Taxes on Income     65       20  
Net loss for the period     16,801       8,501  

 

Revenues

 

Revenues for the nine months ended September 30, 2026 were approximately $5.3 million, an increase of approximately $1.2 million, or 29%, compared to approximately $4.1 million for the nine months ended September 30, 2025. The increase in revenues was primarily attributable to new customers who contributed approximately $1.9 million for the nine months ended September 30, 2026, partially offset by a net decrease of approximately $0.7 million in revenues from other customers, including customers that did not renew their contracts in 2026.

 

ARR

 

Cyabra’s ARR was approximately $8.3 million as of September 30, 2026, compared to approximately $6.7 million as of September 30, 2025, an increase of approximately $1.6 million, or 24%. The increase in ARR was primarily attributable to new customer contracts signed during the twelve months ended September 30, 2026. The increase in ARR reflects the Company’s growing base of recurring customer contracts and may contribute to higher revenues in future periods, subject to the terms and performance of the underlying contracts.

 

Cost of Revenues

 

Cost of revenues for the nine months ended September 30, 2026 was approximately $0.8 million, an increase of approximately $0.2 million, or 37%, compared to approximately $0.6 million for the nine months ended September 30, 2025. The increase in cost of revenues resulted primarily from the growth in revenues.

 

Gross Profit

 

Gross profit for the nine months ended September 30, 2026 was approximately $4.5 million, an increase of approximately $1.0 million, or 28%, compared to approximately $3.5 million for the nine months ended September 30, 2025. The increase resulted primarily from an increase in our revenues.

 

8

 

 

Research and Development Expenses

 

Research and development expenses for the nine months ended September 30, 2026 were approximately $9.7 million, an increase of approximately $4.4 million, or 82%, compared to approximately $5.3 million for the nine months ended September 30, 2025. The increase resulted primarily from an increase in share-based payment expenses and payroll and related personnel expenses of $3.9 million, mainly as a result of expenses related to the closing of the Business Combination, as well as an increase in software expenses.

 

Sales and Marketing Expenses

 

Sales and marketing expenses for the nine months ended September 30, 2026 were approximately $4.0 million, a decrease of approximately $0.4 million, or 10%, compared to approximately $4.4 million for the nine months ended September 30, 2025. The decrease resulted primarily from a decrease in share-based payment expenses and lower marketing expenses as a result of a lower level of marketing activities in the nine months ended September 30, 2026, as well as lower travel expenses.

 

General and Administrative Expenses

 

General and administrative expenses for the nine months ended September 30, 2026 were approximately $8.9 million, an increase of approximately $5.6 million, or 168%, compared to approximately $3.3 million for the nine months ended September 30, 2025. The increase resulted primarily from an increase in professional services expenses, as well as payroll and related personnel expenses and share-based payment expenses, primarily related to the closing of the Business Combination.

 

Operating Loss

 

Operating loss for the nine months ended September 30, 2026 was approximately $18.2 million, an increase of approximately $8.6 million, or 89%, compared to approximately $9.6 million for the nine months ended September 30, 2025, primarily as a result of share-based payment expenses and payroll and related personnel expenses, as well as an increase in professional services expenses mainly in relation to the Business Combination.

 

Finance Expense and Income

 

Finance income for the nine months ended September 30, 2026 was approximately $0.8 million, a decrease of approximately $0.3 million, or 30%, compared to finance income of approximately $1.1 million for the nine months ended September 30, 2025. The decrease in finance income was primarily attributable to an increase in interest expenses, as well as a decrease in non-cash gains recognized from the remeasurement of financial liabilities measured at fair value during the period, partially offset by exchange rate changes.

 

Other Income

 

Other income for the nine months ended September 30, 2026 was approximately $0.6 million, compared to none for the nine months ended September 30, 2025. Other income consisted of a non-recurring gain on settlement of accounts payable.

 

Total Loss

 

Total loss for the nine months ended September 30, 2026 was approximately $16.8 million, an increase of approximately $8.3 million, or 98%, compared to approximately $8.5 million for the nine months ended September 30, 2025. The increase in total loss was primarily as a result of an increase in share-based payment expenses and in payroll and related personnel expenses, as well as a one-time non-recurring expense of $3.4 million related to the Business Combination.

 

9

 

 

Comparison of the three months ended September 30, 2026 to the three months ended September 30, 2025

 

The following table summarizes Cyabra’s results of operations for the three months ended September 30, 2026 and 2025:

 

    Three Months Ended
September 30,
 
    2026     2025  
    USD
Thousands
    USD
Thousands
 
Revenues     2,003       1,487  
Cost of revenues     304       175  
Gross profit     1,699       1,312  
Operating costs and expenses                
Research and development expenses     2,174       1,657  
Sales and marketing expenses     1,432       1,250  
General and administrative expenses     1,310       563  
Total operating loss     3,217       2,158  
Financing expenses, net     5       582  
Other income     (631 )     -  
Loss before taxes on income     2,591       2,740  
Taxes on Income     1       1  
Net loss for the period     2,592       2,741  

 

Revenues

 

Revenues for the three months ended September 30, 2026 were approximately $2.0 million, an increase of approximately $0.5 million, or 35%, compared to approximately $1.5 million for the three months ended September 30, 2025. The increase in revenues was primarily attributable to new customers that contributed approximately $0.3 million in revenues during the three months ended September 30, 2026, as well as increased revenue recognized from existing customers, partially offset by a decrease in revenues from customers that did not renew their contracts in 2026.

 

Cost of Revenues

 

Cost of revenues for the three months ended September 30, 2026 was approximately $0.3 million, an increase of approximately $0.1 million or 74% compared to approximately $0.2 million for the three months ended September 30, 2025. The increase in cost of sales resulted primarily from the growth in revenues.

 

Gross Profit

 

Gross profit for the three months ended September 30, 2026 was approximately $1.7 million, an increase of approximately $0.4 million, or 29%, compared to approximately $1.3 million for the three months ended September 30, 2025. The increase in gross profit resulted from an increase in our revenues.

 

Research and Development Expenses

 

Research and development expenses for the three months ended September 30, 2026 were approximately $2.2 million, an increase of approximately $0.5 million, or 31%, compared to approximately $1.7 million for the three months ended September 30, 2025. The increase in research and development expenses resulted primarily from an increase in payroll and related personnel expenses, an increase in research and development software and storage costs, as well as an increase in share-based payment expenses.

 

10

 

 

Sales and Marketing Expenses

 

Sales and marketing expenses for the three months ended September 30, 2026 were approximately $1.4 million, an increase of approximately $0.1 million, or 15%, compared to approximately $1.3 million for the three months ended September 30, 2025. The increase in sales and marketing expenses resulted primarily from an increase in subcontractor expenses and in share-based payment expenses.

 

General and Administrative Expenses

 

General and administrative expenses for the three months ended September 30, 2026 were approximately $1.3 million, an increase of approximately $0.7 million, or 133%, compared to approximately $0.6 million for the three months ended September 30, 2025. The increase in general and administrative expenses resulted primarily from an increase in professional services, insurance expenses, as well as an increase in share-based payment expenses, travel expenses and payroll and related personnel expenses.

 

Operating Loss

 

Operating loss for the three months ended September 30, 2026 was approximately $3.2 million, an increase of approximately $1.0 million, or 49%, compared to approximately $2.2 million for the three months ended September 30, 2025. The increase in operating loss resulted primarily from the increase in professional services expenses, payroll and related personnel expenses and share-based payment expenses as well as an increase in research and development software and storage, and sales and marketing subcontractors expenses, partially offset by the increase in gross profit.

 

Finance Expense and Income

 

Finance expenses for the three months ended September 30, 2026 were approximately $0.005 million, a decrease of approximately $0.6 million, or 99%, compared to finance expenses of approximately $0.6 million for the three months ended September 30, 2025. The decrease in finance expenses was primarily attributable to exchange rate differences and remeasurement of financial liabilities measured at fair value, both of which resulted in income in the three months ended September 30, 2026, compared to expenses in the corresponding period, as well as a decrease in interest expenses.

 

Other Income

 

Other income for the three months ended September 30, 2026 was approximately $0.6 million, compared to none for the three months ended September 30, 2025, and consisted of the non-recurring gain on settlement of accounts payable described above.

 

Total Loss

 

Total loss for the three months ended September 30, 2026 was approximately $2.6 million, a decrease of approximately $0.1 million, or 5%, compared to approximately $2.7 million for the three months ended September 30, 2025. The decrease in total loss was primarily from an increase in gross profit, decrease in finance expenses and an increase in other income partially offset by an increase in operating expenses.

 

Liquidity and Capital Resources

 

Since our inception through September 30, 2026, we have funded our operations principally through the issuances of equity securities and borrowings. As of September 30, 2026, our cash and cash equivalents were approximately $1.3 million. As of September 30, 2026, we had current assets of approximately $2.4 million and current liabilities of approximately $10.9 million, resulting in a working capital deficit of approximately $8.5 million. We also had a total stockholders’ deficit of approximately $8.5 million as of September 30, 2026.

 

11

 

 

The table below presents our cash flows for the nine-month periods ended September 30, 2026 and September 30, 2025:

 

    Nine months
ended
September 30,
2026
    Nine months
ended
September 30,
2025
 
    USD Thousands     USD Thousands  
Operating Activities     (9,567 )     (6,525 )
Investing Activities     (41 )     (47 )
Financing Activities     10,710       5,627  
Net increase (decrease) in cash     1,102       (945 )

 

Operating Activities

 

Net cash used in operating activities was approximately $9.6 million during the nine months ended September 30, 2026, compared to approximately $6.5 million during the nine months ended September 30, 2025. The increase in net cash used in operating activities was primarily attributable to an increase in net loss of approximately $8.3 million, partially offset by the combined effect of non-cash expenses and changes in working capital of approximately $5.2 million, mainly related to share-based payments, including share-based payments for advisory services and shares issued to advisors in connection with the Business Combination.

 

Investing Activities

 

Net cash used in investing activities was approximately $0.04 million during the nine months ended September 30, 2026, compared to approximately $0.05 million during the nine months ended September 30, 2025.

 

Financing Activities

 

Net cash provided by financing activities was approximately $10.7 million during the nine months ended September 30, 2026, compared to approximately $5.6 million during the nine months ended September 30, 2025. The increase in net cash provided by financing activities resulted primarily from net proceeds from private investment in public equity (PIPE) transactions and cash received upon the closing of the Business Combination during the nine months ended September 30, 2026. These were partially offset by an increase in repayment of loans and a decrease in proceeds from loans compared to the nine months ended September 30, 2025. 

 

Cyabra will need to raise additional capital to support its operations until such time, if any, as it is able to generate sufficient cash to fund its working capital requirements. Cyabra may not be able to obtain additional financing on acceptable terms, or at all. To the extent that Cyabra raises additional capital through the future sale of equity or debt, the ownership interest of its shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of Cyabra’s existing shareholders. If Cyabra raises additional funds through partnerships or strategic alliances in the future, it may have to relinquish valuable rights to its technologies, future revenue streams or products or grant licenses on terms that may not be favorable to Cyabra.

 

12

 

 

On July 9, 2026, Cyabra entered into securities purchase agreements (each, a “Purchase Agreement”) with accredited investors relating to an offering (the “Offering”) and the sale of an aggregate of 1,175,090 shares (the “Shares”) of common stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 12,643,680 shares of common stock (the “Pre-Funded Warrant Shares”), at a purchase price of $0.435 per Share and $0.4349 per Pre-Funded Warrant, Series A warrants (the “Series A Common Warrants”) to purchase up to 13,818,770 shares of common stock (the “Series A Common Warrant Shares”), at an exercise price of $0.50 and Series B warrants (the “Series B Common Warrants”) to purchase up to 13,818,770 shares of common stock (the “Series B Common Warrant Shares”), at an exercise price of $0.45. The Offering closed on July 10, 2026. The gross proceeds from the Offering, before deducting the placement agent fees and offering expenses, were approximately $6 million.

 

The Pre-Funded Warrants are exercisable immediately upon issuance and remain exercisable until exercised in full. The Series A Common Warrants became exercisable on September 2, 2026, the date stockholder approval (the “Stockholder Approval”) was obtained, and will expire five years from that date. The Series B Common Warrants became exercisable on September 2, 2026 and will expire twelve months from that date.

 

In conjunction with the Offering, Cyabra engaged A.G.P./Alliance Global Partners, as exclusive placement agent and agreed to pay the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds raised from the sale of the securities sold in the Offering, and agreed to reimburse the placement agent for accountable legal fees and other reasonable and documented out-of-pocket expenses incurred in connection with the transaction in the amount of up to $75,000 and the reimbursement of up to $15,000 for non-accountable expenses.

 

On July 9, 2026, Cyabra entered into an exchange agreement (the “Exchange Agreement”) with Alpha Capital Anstalt (the “Holder”) that holds the outstanding Series C Convertible Preferred Stock (“Series C Preferred Shares”), pursuant to which the Holder agreed to exchange at the Exchange Closing (as defined in the Exchange Agreement) an amount of Series C Preferred Shares with an aggregate value of $10,660,000 (the “Preferred Shares Value”), and Cyabra agreed to issue to the Holder, in the exchange therefor: (i) the number of shares of Common Stock; (ii) if applicable, the Pre-Funded Warrants; and (iii) the Series A Common Warrants and the Series B Common Warrants (including the Series A Common Warrant Shares and the Series B Common Warrant Shares) as if the Holder had invested additional cash equal to the Preferred Shares Value in the Offering. Upon the Exchange Closing, the Exchange Preferred Shares (as defined in the Exchange Agreement) were automatically cancelled, retired and restored to the status of authorized but unissued shares of Series C Preferred Shares.

 

On July 9, 2026, Cyabra entered into a conversion agreement (the “Conversion Agreement”) with the holders (the “Holders”) of an aggregate of 15,507 shares of Series A Preferred Shares and Series B Convertible Preferred Stock (“Series B Preferred Shares” and together with the Series A Preferred Shares, the “Preferred Shares”), convertible into an aggregate of 35,648,276 shares of common stock at the reduced conversion price described below, pursuant to which the Holders agreed that upon the Conversion Closing (as defined in the Conversion Agreement), all of the outstanding Preferred Shares (the “Committed Preferred Shares”) would be deemed to have been converted (the “Conversion”) into shares of Common Stock (or pre-funded warrants in lieu thereof). Pursuant to the Conversion Agreement, Cyabra and the Holders agreed to amend the terms of the Certificates of Designation governing the Preferred Shares to reduce the conversion price of each class of Preferred Shares to $0.435 per share.

 

On September 2, 2026, Cyabra’s stockholders approved the Conversion and the Exchange. The Conversion Closing and the Exchange Closing occurred on September 9, 2026, upon which all outstanding Series A Preferred Shares, Series B Preferred Shares and Series C Preferred Shares were converted into, or exchanged for, shares of Common Stock, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants. As of September 30, 2026, no preferred shares were outstanding.

 

13

 

 

If Cyabra is unable to raise additional funds when needed, Cyabra may be required to delay, limit, reduce or terminate its product development or future commercialization efforts.

 

In connection with Cyabra’s assessment of going concern considerations in accordance with the authoritative guidance in Financial Accounting Standard Board Accounting Standards Update 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that Cyabra currently lacks the liquidity it needs to sustain operations for a reasonable period of time, which is considered to be at least one year from the date that the financial statements are issued as it expects to continue to incur significant costs. There are no assurances however, that Cyabra will be successful in obtaining the level of financing needed for its operations. If Cyabra is unsuccessful in commercializing its products and securing sufficient funding, it may need to reduce activities, curtail, or even cease operations. The consolidated financial statements do not include any adjustments relating to the carrying amounts and classification of assets, liabilities, and reported expenses that might be necessary should Cyabra be unable to continue as a going concern.

 

Nasdaq Listing Compliance

 

The Company has previously received notices from the Listing Qualifications Department of Nasdaq indicating that the Company does not comply with the continued listing requirements of the Nasdaq Global Market relating to (i) the minimum market value of listed securities, (ii) the minimum market value of publicly held shares and (iii) the minimum bid price of its common stock.

 

In response to these deficiencies, the Company has been evaluating available alternatives to regain compliance.

 

 As previously disclosed, on June 9, 2026, the Company received a notice from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market (“Nasdaq”) that based on its Market Value of Listed Securities (“MVLS”) for the period from March 27, 2026 through May 12, 2026, the Company no longer met the continued listing requirement of Nasdaq under Listing Rule 5450(b)(2)(A), to maintain a minimum MVLS of $50,000,000. In accordance with Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with a compliance period of 180 calendar days, or until November 9, 2026, in which to regain compliance with Nasdaq continued listing requirement.

 

On November 16, 2026, the Company received a letter (the “Delist Determination Letter”) from Staff notifying that it had not regained compliance with MVLS Nasdaq rule. Accordingly, its securities will be delisted from The Nasdaq Global Market. In that regard, unless the Company requests an appeal of this determination by November 23, 2026, trading of the Company’s securities will be suspended at the opening of business on November 25, 2026, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. The Company intends to timely submit its hearing request, which will stay the suspension.

 

The Company also remains subject to non-compliance with (i) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly Held Shares, or MVPHS, of $15 million, and (ii) Nasdaq Listing Rule 5450(a)(1) due to the failure of its common stock to maintain a minimum bid price of $1.00 per share for the 30 consecutive business days ended June 8, 2026. In accordance with Nasdaq Listing Rule 5810(c)(3)(D), we have a compliance period of 180 calendar days from the date of the notice, or until December 7, 2026, and we may regain compliance if at any time during the compliance period the MVPHS closes at $15 million or more for a minimum of ten consecutive business days. In addition, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided a compliance period of 180 calendar days, or until December 7, 2026, in which to regain compliance with the minimum bid price rule.

 

There can be no assurance that the Company will regain compliance with the minimum bid price requirement within any applicable compliance period. If the Company is unable to maintain its Nasdaq listing, the liquidity and market price of its common stock and its ability to raise additional capital could be materially adversely affected.

 

14

 

 

Reverse Stock Split

 

In connection with the Company’s efforts to regain compliance with Nasdaq’s minimum bid price requirement, the Company’s Board of Directors has approved a reverse stock split of the Company’s outstanding common stock at a ratio of 1-for-30, subject to stockholder approval. The proposed reverse stock split was approved at the Company’s annual meeting of stockholders on November 10, 2026.

 

There can be no assurance that the reverse stock split will be implemented or that it will result in the Company regaining or maintaining compliance with Nasdaq’s minimum bid price requirement.

 

Subsequent Financing Transactions

 

On November 15, 2026, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with Alpha Capital Anstalt and certain other purchasers, pursuant to which the Company agreed to issue and sell shares of newly designated Series D Convertible Preferred Stock (the “Series D Preferred Stock”) and warrants to purchase shares of the Company’s common stock (the “Warrants”) in a private placement offering for aggregate consideration of up to approximately $45.6 million. The Series D Preferred Stock will have a stated value of $1,000 per share and will be convertible into common stock at an initial conversion price of $0.15 per share, subject to adjustment. The Warrants will have an initial exercise price of $0.15 per share, subject to adjustment, and will become exercisable following receipt of the required stockholder approval. The initial closing is expected to involve an aggregate subscription amount of approximately $15.6 million, consisting of $10 million in new investment and approximately $5.6 million in subscription consideration to be satisfied through the cancellation of approximately $2.8 million of outstanding indebtedness of the Company, including certain obligations originally owed to Loeb & Loeb LLP that were assigned to Alpha Capital Anstalt on November 2, 2026. The initial closing is subject to certain conditions, including required stockholder approvals and confirmation from Nasdaq that the Company has cured its listing deficiencies and that its continued listing has been approved. As of the date of this Quarterly Report on Form 10-Q, the initial closing has not occurred.

 

The Securities Purchase Agreement also provides for potential additional investments of up to $30 million over a three-year period, subject to the terms and conditions set forth therein. There can be no assurance that any such additional investments will occur or that the initial closing will be consummated.

 

On November 9, 2026, the Company entered into a Secured Promissory Note and Security Agreement (the “Note Agreement”) with Alpha Capital Anstalt (the “Lender”), pursuant to which the Lender agreed to provide financing to the Company in an aggregate principal amount of up to $1.5 million, to be funded in tranches mutually agreed upon by the Company and the Lender. An initial tranche in the principal amount of $650,000 was funded on November 9, 2026.

 

The outstanding principal amount under the Note Agreement bears interest at a rate of 10% per annum, increasing to the lesser of 18% per annum or the maximum rate permitted by applicable law upon the occurrence and during the continuance of an event of default. The outstanding principal amount, together with accrued interest, is due on January 15, 2027, subject to the Lender’s right to extend the maturity date in three-month increments through December 31, 2028.

 

The Company’s obligations under the Note Agreement are secured by a security interest in substantially all of the Company’s assets, including certain intellectual property and equity interests in its subsidiaries, subject to certain exceptions and required consents, including with respect to assets subject to restrictions imposed by the Israel Innovation Authority.

 

The Note Agreement contains customary representations, warranties, covenants and events of default. Upon an event of default, the outstanding principal amount becomes immediately due and payable, and the Lender may exercise its rights and remedies as a secured creditor.

 

Off-Balance Sheet Arrangements

 

Cyabra did not have any off-balance sheet arrangements as of September 30, 2026.

  

15

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, we are not required to provide the information called for by this item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, and the rules and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

As required by Rule 13a-15(b) under the Exchange Act, our management, under the supervision and with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and implementation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were effective at the reasonable assurance level.

 

Changes in Internal Control Over Financial Reporting

 

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Inherent Limitations on Effectiveness of Controls

 

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

16

 

 

Part II

 

ITEM 1. LEGAL PROCEEDINGS.

 

We may, from time to time, become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that may be, individually or in the aggregate, material to us.

 

ITEM 1A. RISK FACTORS.

 

Our business is subject to substantial risks and uncertainties. An investment in our securities involves a high degree of risk. The information presented below supplements the risk factors previously disclosed in “Part I, Item 1A. Risk Factors,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC on March 26, 2026 (our “Annual Report”) and in “Form 10 Information - Risk Factors” in our Current Report on Form 8-K, as filed with the SEC on March 31, 2026 (the “Form 8-K”). In addition to the other information set forth in this report and in our other SEC filings from time to time, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” in our Annual Report and in “Form 10 Information - Risk Factors” in Form 8-K, as supplemented by the information below, which could materially affect our business, financial condition or future results. The risks described in our Annual Report and Form 8-K, as supplemented by the information below, may not be the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. Except as required by the federal securities law, we undertake no obligation to update or revise any risk factor, whether as a result of new information, future events or otherwise.

 

We have failed to regain compliance with certain Nasdaq continued listing requirements, and our common stock may be delisted from Nasdaq, which could materially adversely affect the liquidity and market price of our common stock and our ability to raise capital.

 

As previously disclosed, we have received notices from Nasdaq indicating that we are not in compliance with certain continued listing requirements of the Nasdaq Global Market, including the minimum market value of listed securities, minimum market value of publicly held shares and minimum bid price requirements.

 

We were afforded a compliance period through November 9, 2026, to regain compliance with Nasdaq's minimum MVLS requirement. We did not regain compliance by that deadline and on November 16, 2026 we received the Delist Determination Letter from Staff notifying that we have not regained compliance with MVLS Nasdaq rule. In that regard, unless we request an appeal of this determination by November 23, 2026, trading of the Company’s securities will be suspended at the opening of business on November 25, 2026. We intend to timely submit a hearing request, which will stay the suspension.

 

We have been pursuing measures intended to address our listing deficiencies, including a reverse stock split and additional financing transactions. However, there can be no assurance that we will satisfy the applicable listing requirements, or that any appeal or other remedial measures will be successful.

 

If our common stock is delisted from Nasdaq, the liquidity and market price of our common stock could be materially adversely affected, investors could experience greater difficulty purchasing or selling our securities, and our ability to raise additional capital could be significantly impaired. Delisting could also adversely affect our relationships with investors, customers and other business partners and could result in additional costs and regulatory consequences.

 

Our ability to obtain additional financing is uncertain, and the failure to consummate our recently announced private placement could materially adversely affect our liquidity, financial condition and ability to continue operations.

 

On November 15, 2026, we entered into a Securities Purchase Agreement with Alpha Capital Anstalt and certain other purchasers, pursuant to which we agreed to issue and sell shares of Series D Preferred Stock and warrants in a private placement offering. The transaction contemplates an initial closing with an aggregate subscription amount of approximately $15.6 million, including $10 million of new investment and approximately $5.6 million in subscription consideration to be satisfied through cancellation of approximately $2.8 million of outstanding indebtedness. The agreement also contemplates potential additional investments of up to $30 million over a three-year period.

 

The initial closing remains subject to significant conditions, including required stockholder approvals and confirmation from Nasdaq that we have cured our listing deficiencies and that our continued listing has been approved. As discussed above, we did not regain compliance with Nasdaq's minimum MVLS requirement by the November 9, 2026 deadline. Accordingly, there is substantial uncertainty regarding our ability to satisfy the conditions to the initial closing.

 

There can be no assurance that the initial closing will occur, that the purchasers will waive any unsatisfied conditions or that any subsequent investments will be made. Until the initial closing occurs, we will not have received the anticipated proceeds from the private placement, and we cannot rely on such proceeds to fund our operations.

 

We have incurred significant operating losses and have substantial liquidity needs. If the private placement is not consummated, or if we are unable to obtain sufficient alternative financing on acceptable terms, we may be required to reduce or delay our operating activities, research and development expenditures or other planned investments, and our ability to continue operations could be materially adversely affected.

 

17

 

 

The issuance of securities in our proposed private placement could result in substantial dilution to our existing stockholders and adversely affect the market price of our common stock.

 

If the proposed private placement is consummated and the required stockholder approvals are obtained, the conversion of the Series D Preferred Stock and exercise of the Warrants could result in the issuance of a substantial number of additional shares of our common stock. The conversion and exercise prices are subject to adjustment under certain circumstances, which could result in additional issuances. Such issuances could substantially dilute the ownership and voting interests of our existing stockholders. In addition, the actual or anticipated issuance or resale of a substantial number of shares of common stock could adversely affect the market price of our common stock and our ability to raise additional equity capital on favorable terms.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

There were no unregistered sales of equity securities during the period covered by this report.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

During the fiscal quarter ended September 30, 2026, none of our officers or directors, as those terms are defined in Rule 16a-1(f), adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.

 

Nasdaq Listing Compliance

 

As previously disclosed, on June 9, 2026, the Company received a notice from the Staff of Nasdaq that based on its MVLS for the period from March 27, 2026 through May 12, 2026, the Company no longer met the continued listing requirement of Nasdaq under Listing Rule 5450(b)(2)(A), to maintain a minimum MVLS of $50,000,000. In accordance with Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with a compliance period of 180 calendar days, or until November 9, 2026, in which to regain compliance with Nasdaq continued listing requirement.

 

On November 16, 2026, the Company received the Delist Determination Letter from Staff notifying that it had not regained compliance with MVLS Nasdaq rule. Accordingly, its securities will be delisted from The Nasdaq Global Market. In that regard, unless the Company requests an appeal of this determination by November 23, 2026, trading of the Company’s securities will be suspended at the opening of business on November 25, 2026, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. The Company intends to timely submit its hearing request, which will stay the suspension.

 

18

 

 

ITEM 6. EXHIBITS

 

Exhibit   Description   Schedule/
Form
  File
Number
  Exhibit   File Date
2.1   Merger Agreement, as amended.   S-4/A   333-283153   2.1   January 13, 2026
3.1   Certificate of Incorporation of Cyabra, Inc.   8-K   001-43214   3.1   March 31, 2026
3.2   Bylaws of Cyabra, Inc.   S-4/A   333-283153   3.7   January 13, 2026
3.3   Amendment No. 1 to the Amended and Restated Bylaws of Cyabra, Inc.   8-K   001-43214   3.1   July 31, 2026
3.4   Certificate of Designation of Holdings relating to the Series A Convertible Preferred Stock.   8-K   001-43214   3.3   March 31, 2026
3.5   Certificate of Designation of Holdings relating to the Series B Convertible Preferred Stock.   8-K   001-43214   3.4   March 31, 2026
3.6   Certificate of Designation of Holdings relating to the Series C Convertible Preferred Stock.   8-K   001-43214   3.5   March 31, 2026
3.7   Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock   8-K   001-43214   3.1   July 10, 2026
3.8   Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock   8-K   001-43214   3.2   July 10, 2026
3.9   Certificate of Designation of Cyabra, Inc. relating to the Series D Convertible Preferred Stock.   8-K   001-43214   3.1   November 16, 2026
4.1   Form of Common Stock Purchase Warrant.   8-K   001-43214   10.25   March 31, 2026
4.2   Form of Pre-Funded Warrant.   8-K   001-43214   4.1   July 10, 2026
4.3   Form of Series A Common Warrant.   8-K   001-43214   4.2   July 10, 2026
4.4   Form of Series B Common Warrant.   8-K   001-43214   4.3   July 10, 2026
4.5   Form of Common Stock Purchase Warrant issued pursuant to the Securities Purchase Agreement dated November 15, 2026.   8-K   001-43214   4.1   November 16, 2026
10.1†   Cyabra, Inc. 2026 Omnibus Equity Incentive Plan.   8-K   001-43214   10.4   March 31, 2026
10.2†   Form of Incentive Stock Option Grant Agreement under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan.   S-4/A   333-283153   10.23   December 20, 2024
10.3†   Form of Non-Qualified Stock Option Grant Agreement under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan.   S-4/A   333-283153   10.24   December 20, 2024
10.4†   Form of Section 102 Restricted Stock Unit Agreement under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan.   8-K   001-43214   10.7   March 31, 2026
10.5†   Form of Restricted Stock Unit Agreement under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan.   S-4/A   333-283153   10.25   December 20, 2024
10.6†   Form of Restricted Stock Award Agreement under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan.   S-4/A   333-283153   10.26   December 20, 2024
10.7†   Form of Section 3(i) Option Grant Agreement under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan and 2026 Israeli Sub-Plan.   S-4/A   333-283153   10.27   December 20, 2024
10.8†   Form of Section 102 Option Grant Agreement under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan and 2026 Israeli Sub-Plan.   S-4/A   333-283153   10.28   December 20, 2024
10.9   Offer of Employment, dated December 29, 2022 by and between Cyabra Strategy Inc. and Emmanuel Heymann.   S-4/A   333-283153   10.36   January 13, 2026
10.10   Facility Agreement, dated May 30, 2022, between Cyabra and Bank Hapoalim B.M.   S-4/A   333-283153   10.31   January 13, 2026
10.11   Employment Agreement dated June 18, 2024 by and between Cyabra Strategy Ltd. and Yael Sandler.   S-4/A   333-283153   10.37   January 13, 2026
10.12   Amendment to Offer of Employment, by and between Cyabra Strategy Inc. and Emmanuel Heymann, dated August 15, 2024.   S-4/A   333-283153   10.38   January 13, 2026
10.13   Form of Indemnification Agreement.   S-4/A   333-283153   10.39   January 13, 2026
10.14   Registration Rights Agreement, dated March 27, 2026, between Trailblazer Holdings, Inc. and certain investors.   8-K   001-43214   10.19   March 31, 2026
10.15   Offer of Employment, dated February 10, 2025 by and between Cyabra Strategy Inc. and Dan Brahmy.   S-4/A   333-283153   10.40   January 13, 2026
10.16   Amendment to Employment Agreement dated February 10, 2025 by and between Yossef Daar and Cyabra Strategy Ltd.   S-4/A   333-283153   10.41   January 13, 2026
10.17   Amendment to Employment Agreement dated February 10, 2025 by and between Ido Shraga and Cyabra Strategy Ltd.   S-4/A   333-283153   10.42   January 13, 2026
10.18   Securities Purchase Agreement dated December 18, 2025, between Trailblazer Holdings, Inc. and certain purchasers.   S-4/A   333-283153   10.45   January 13, 2026

 

19

 

 

Exhibit   Description   Schedule/
Form
  File
Number
  Exhibit   File Date
10.19   Form of Common Stock Purchase Warrant.   8-K   001-43214   10.25   March 31, 2026
10.20   Note Issuance Agreement among Cyabra, Trailblazer Merger Corporation I, Trailblazer Holdings, Inc. and Lowenstein Sandler LLP.   S-4/A   333-283153   10.52   January 13, 2026
10.21   Note Issuance Agreement among Cyabra, Trailblazer Merger Corporation I, Trailblazer Holdings, Inc. and Loeb & Loeb LLP.   S-4/A   333-283153   10.53   January 13, 2026
10.22   Promissory Note, dated February 4, 2026.   8-K   001-43214   10.32   March 31, 2026
10.23   Promissory Note, dated March 9, 2026.   8-K   001-43214   10.33   March 31, 2026
10.24   Amendment to Employment Agreement, dated March 16, 2026, between Cyabra, Inc. and Yossef Daar.   8-K   001-43214   10.34   March 31, 2026
10.25   Amendment to Employment Agreement, dated March 16, 2026, between Cyabra, Inc. and Ido Shraga.   8-K   001-43214   10.35   March 31, 2026
10.26   Form of Securities Purchase Agreement   8-K   001-43214   10.1   July 10, 2026
10.27   Placement Agent Agreement, dated July 9, 2026, by and between Cyabra, Inc. and A.G.P./Alliance Global Partners   8-K   001-43214   10.2   July 10, 2026
10.28   Form of Conversion Agreement   8-K   001-43214   10.3   July 10, 2026
10.29   Exchange Agreement, dated July 9, 2026, by and between Cyabra, Inc. and Alpha Capital Anstalt   8-K   001-43214   10.4   July 10, 2026
10.30   Secured Promissory Note and Security Agreement, dated November 9, 2026, by and between Cyabra, Inc. and Alpha Capital Anstalt.   8-K   001-43214   10.1   November 10, 2026
10.31   Securities Purchase Agreement, dated November 15, 2026, by and between Cyabra, Inc. and the purchaser identified therein.   8-K   001-43214   10.1   November 16, 2026
10.32   Registration Rights Agreement, dated November 15, 2026, by and between Cyabra, Inc. and the purchaser identified therein.   8-K   001-43214   10.2   November 16, 2026
31.1*   Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)                
31.2*   Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)                
32.1*   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350                
101.INS*   Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document                
101.SCH*   Inline XBRL Taxonomy Extension Schema Document                
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document                
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document                
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document                
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document                
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)                

 

* Furnished herewith.
   
** The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and will not be deemed to be incorporated by reference into any filing under such Act or the Securities Act of 1933, as amended, except to the extent that the registrant specifically incorporates such certifications by reference.

 

† Annexes, schedules and exhibits to this Exhibit omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

  

20

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Cyabra, Inc.
(Registrant)
   
Date: November 16, 2026 By: /s/ Dan Brahmy
    Dan Brahmy
    Chief Executive Officer
    (Principal Executive Officer)
   
Date: November 16, 2026 By: /s/ Yael Sandler
    Yael Sandler
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

21

 

Keep reading